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The purpose of this study was to determine if diet and/or body composition 
influences resting plasma apelin concentration. Apelin concentration appears to be 
influenced by the amount of fat in the body and by blood glucose concentration.  
However, most of the studies that have investigated blood apelin concentration have 
utilized obese or diabetic subjects.  Little is known about how body composition, body fat 
distribution or diet may influence apelin in apparently healthy, young individuals. More 
specifically, the purposes of this study were to determine if baseline resting plasma apelin 
concentration in young, apparently healthy adult subjects is influenced by amount of fat 
in the body, location of fat, the macronutrient composition in their diet and if the total 
amount of antioxidant micronutrients (vitamins A, C, E and zinc). The proposed cohort 
group consisted of twelve apparently healthy young adults between the ages of 18-35.The 
amount of body fat, body mass index, sagittal diameter and the waist to hip ratio were 
utilized as covariates to determine if these factors influenced apelin concentration at rest.  
The data was analyzed to ascertain if there are any relationships with the listed 
anthropometric measures, the nutrition factors and plasma apelin concentration.  Each 
subject’s body composition was classified via body mass index (BMI), sagittal abdominal 
diameter (SAD), waist circumference (WC) and 7-site skinfold analysis. In addition, 
Each subject completed a three day diet record prior to their three visits which were 
analyzed for total calories, macronutrient percent calories and amount of micronutrient 
antioxidants; vitamin A, C, E, and zinc.  They were instructed on how to log 3 day diet 
records and were asked to repeat the diets as close as possible on their 2nd and 3rd visits to 
keep this information as consistent as possible. Significant relationships were found for 
body composition factors including Siri % body fat (r=0.631, P=0.028*), Brozek % body 
fat (r=0.642, P=0.024*), and BMI (r=0.649, P=0.022*).  Body composition factors 
showed varied results.  A significant association was found between sagittal abdominal 
diameter and plasma apelin concentrations at rest (r=0.628, p=0.029*), however waist 
circumference approached significance (r=0.061, P=0.061) and waist-to-hip ratio did not 
demonstrate a significant relationship (r=0.178, P=0.579).  Only two subjects reported 
consuming high fat diets (>35% of total kilocalorie intake), therefore no relationships 
could be analyzed regarding plasma apelin concentration at rest and high fat diets.  No 
significant relationships were found between individual micronutrients and plasma apelin 
concentrations at rest, besides vitamin E (r=0.658, P=0.020*). In conclusion this small 
cohort of subjects had stable resting plasma apelin levels across visits and does not 
appear that dietary factors influenced plasma apelin concentrations. In contrast, % BF and 
SAD suggest that these factors are significantly related to resting plasma apelin, with WC 
also approaching significance. More research should be done with a larger cohort of 
subjects including a wider range of diet and anthropometric measures. 
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CHAPTER I 
INTRODUCTION 
 
 
 Due to the exorbitant health care costs associated with the conditions and diseases 
associated with being classified as overweight or obese there has been much interest in 
obesity research.  The National Health and Nutrition Examination Survey (NHANES) 
conducted by the Center for Disease Control and Prevention (CDC) provides longitudinal 
insight on the obesity trends in the United States via Body Mass Index (BMI) calculations 
collected in labs across the country (Flegal, 2012).  The NHANES 2009-2010 data 
showed that the age-adjusted obesity (BMI ≥ 30) prevalence for both men and women 
was 35.7%, with no significant difference in prevalence between genders(Flegal, 2012).  
More alarmingly, the age-adjusted prevalence for overweight and obesity in both genders 
(BMI ≥ 25) was calculated to be 68.8% (Flegal, 2012).  BMI is an important tool in 
assessing the weight status of populations, but on an individual basis, obesity is more 
accurately defined as greater than two standard deviations above the norm for percent 
body fat (%BF).  The normal %BF for young men is 15 ± 5% and women is 21± 
5%.Therefore, obesity would be considered greater than 25% body fat in young men and 
greater than 32% body fat in young women.   On an international level, statistics show 
that about 1 billion people worldwide are overweight, with 300 million being obese 
(Bełtowski, 2006).
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Table 1. BMI Normative Data. Source: US Dept. of Health and Human Services: NIH 
National Heart, Lung and Blood Institute 
http://www.nhlbi.nih.gov/health/educational/lose_wt/BMI/bmi_dis.htm 
 
BMI Normative Data 
 
Category BMI 
(kg/m2) 
Disease Risk Relative to Normal Weight 
& Waist Circumference 
Underweight < 18.5 Men < 102 
cm 
Men > 102 cm 
Normal 18.5-24.9 Women <88 
cm 
Women > 88 cm 
Overweight 25.0-29.9 Increased High 
Obesity (I) 30.0-34.9 High Very High 
Obesity (II) 35.0-39.9 Very High Very High 
Extreme Obesity 
(III) 
> 40.0 Extremely 
High 
Extremely High 
 
 
Table 2. Percent Body Fat Normative Data. Source: ACSM, 2006; IOM, 2002 
 
Percent Body Fat Normative Data 
 
Source: ACSM, 2006 IOM, 2002 
Category (Percentile) Men (20-
29) 
Women (20-
29) 
Categor
y 
Men Women 
Excellent (80-100) 5-10% 12-17% Excellent 10-
15% 
20-24% 
Good (60-79) 10.1-14% 17.1-21% Good 16-
20% 
25-30% 
Average (40-59) 14.1-17% 21.1-24% Overwei
ght 
21-
24% 
31-36% 
Low (20-39) 17.1-22% 24.1-28% Obese 25-
30% 
37-41% 
At Risk (0-19) > 22% > 28% High 
Risk 
> 
31% 
> 42% 
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The obesity epidemic is of particular importance due to increased prevalence of 
comorbidities and disease including but not limited to Type 2 Diabetes (T2D), 
cardiovascular disease (CVD), hypertension (HTN), hyperlipidemia and several types of 
cancers, as well as musculoskeletal, sleep and gallbladder problems (Dusserre, Moulin, & 
Vidal, 2000; Finkelstein, Fiebelkorn, & Wang, 2004).Obesity-related medical 
complications contribute substantially to the United States’ $75 billion spent annually on 
medical expenditures, with an estimated 50% being funded by Medicare and Medicaid 
(Finkelstein et al., 2004).  Estimates show that compared to normal weight individuals, 
obese patients incurred 36% greater medical expenses(Sturm, 2002).  
 It has been shown that obese patients are at increased risk for T2D, which is 
related to insulin resistance (IR)(N. P. E. Kadoglou, Vrabas, Kapelouzou, & 
Angelopoulou, 2012).   Yue et al., defines insulin resistance as, “a diminution in a cell, 
tissue or organism’s ability to take up glucose in response to insulin, [and] is the 
pathophysiological hallmark of type 2 diabetes mellitus” (Yue et al., 2010).Insulin 
resistance can be determined by the amount of insulin needed to handle a specific glucose 
load.  Obesity-related IR occurs in a number of metabolic tissues including the liver, 
skeletal muscle, and adipose tissue (AT). 
Obesity is linked to many variables, most commonly including sedentary behavior 
and overeating.  The increased adiposity associated with high caloric consumption and 
imbalances in macronutrient intake has been shown to induce hypertrophic obesity, the 
increase in size of fat cells and or hyperplastic obesity, an increase in number of fat cells, 
or a combination of the two (Jo et al., 2009).    
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Nutrition, for example, total calorie consumption and the percentage breakdown 
of macronutrients, particularly the amount of fat in the diet can influence amount of AT 
stores. An overconsumption of macronutrients, including carbohydrates (CHO), protein, 
and/or lipids is termed nutrient overload and may contribute to metabolic dysfunction and 
ultimately IR.  Similarly, an imbalance in consumption of the recommended ranges of 
macronutrients, along with the “nutrient overload” may lead to obesity along with 
increased risk for T2D(Alhazmi, Stojanovski, McEvoy, & Garg, 2012).  Meta-analyses 
showed that high CHO and high fat diets (HFD) play a role in altering insulin resistance, 
and thus, risk for T2D (Alhazmi et al., 2012).  High caloric intake of these nutrients leads 
to storage of triglycerides (TGs) in white adipose tissue (WAT), inducing adipose tissue 
expansion, and ultimately increased body fat, possibly inducing obesity.  The 
overconsumption of CHOs and fats overload the body with calories, in which case the 
excess is stored as fat. The increased risk associated with high-CHO diets is due to the 
high glycemic index/load, which may lead to increased insulin demand, elevated plasma 
glucose concentrations, and ultimately contributing to pancreatic failure and glucose 
intolerance (T2D) (Alhazmi et al., 2012).  It has also been reported that females 
consuming diets high in vegetable fats may see a decreased risk for T2D and increased 
insulin sensitivity through improvement in lipid profiles and better glycemic control in 
diabetics (Alhazmi et al., 2012). 
Along with macronutrient consumption, intake of micronutrients also plays a 
significant role in proper physiological functioning of the body.  Micronutrients are 
substances (vitamins and minerals), which are required, albeit in small amounts, for 
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proper development as well as prevention of disease and dysfunction (CDC, Linus-
Pauling Institute).It is important that the diet consists of adequate amounts of 
micronutrient vitamin and minerals for proper physiological functioning; micronutrients 
are not synthesized by the body, therefore adequate consumption is required, as they must 
be derived from dietary intakes (CDC, LPI).  
 There are several noteworthy physiological complications associated with 
overweight and obese status.  Insulin resistance, chronic inflammation, and oxidative 
stress are three possible physiologically significant consequences seen in overweight or 
obese humans.  Due to WAT’s plasticity, an increased amount of adipose tissue is a 
characteristic of obesity and may illicit metabolic changes (McArdle, Finucane, 
Connaughton, McMorrow, & Roche, 2013).  These processes are thought to be regulated 
by various molecules secreted and released by adipocytes within the adipose tissue called 
“adipokines” or “adipocytokines.”  These molecules are thought to regulate many 
physiological processes associated with complications experienced due to overweight or 
obese states.   
Recently, apelin, an adipokine, has been implicated in the regulation of obesity 
and increased risk of T2D.  This recently discovered adipokine, is a signaling molecule 
which works on the APJ receptor, originates in adipose tissue, and may be affected by 
blood glucose levels and states of obesity as well as the amounts of vitamin C and insulin 
present(García-Díaz, Campión, Milagro, & Martínez, 2007; Langelaan, Bebbington, 
Reddy, & Rainey, 2009).  It has been suggested that apelin expression is mediated by the 
severity of IR in diabetic subjects and by its location in various tissues (Dray et al., 
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2010).  A recent review discussed the etiology of IR as “diet-induced” via nutrient 
overload, through which cellular reduction is increased in the mitochondria, thus 
elevating the concentrations of hydrogen peroxide (H2O2) a potent radical inducer, 
creating a metabolic imbalance (Fisher-Wellman & Neufer, 2012).  
Constant nutrient overload can influence reactive oxygen species (ROS) 
production and IR, inducing a state of chronic low-grade inflammation, oxidative stress, 
and possibly influencing apelin concentration(Garcia-Diaz et al., 2011).  The expansion 
of AT due to increasing lipid droplet size has recently been implicated in the increased 
secretion and regulation of inflammatory cytokines, which was associated with the 
chronic state of low-grade inflammation and obesity along with IR-induced diabetes 
mellitus (Galic, Oakhill, & Steinberg, 2010).Thus, the amount of AT and potentially the 
site of adiposity can influence not only ROS, but also inflammation, and theoretically IR. 
Along with general obesity complications, it is commonly known that there is increased 
metabolic risk associated with carrying visceral (abdominal/central) adiposity as opposed 
to gynoid (peripheral/gluteophemoral) adiposity, likely due to increased free fatty acid 
circulation (Smith et al., 2001).  Interestingly, studies have shown that lean subjects with 
an elevated waist-to-hip ratio (WHR), indicating central adiposity, have the highest risk 
for cardiovascular (CV) risk factors including IR, dyslipidemia, HTN, smoking, 
fibrinolysis, and various psychosocial factors (Björntorp, 1997).  More recently, studies 
have taken into account sagittal abdominal diameter (SAD) as a correlate for elevated CV 
risk. 
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Table 3.  Cutoffs for Determining Elevated Cardiovascular Risk.  Lists the cutoffs for 
Sagittal Abdominal Diameter (SAD), Waist Girth (WG), Waist-Hip-Ratio (WHR), and 
Body Mass Index (BMI in kg/m2).Journal of Obesity (2010). 
 
Cutoffs for Determining Elevated Cardiovascular Risk 
 
Measure Men (95% CI) Women (95% CI) 
SAD (cm) 22.2 (21.6-22.8) 20.1 (19.4-20.8) 
WG (cm) 100 (96.9-101) 88.4 (86.7-90) 
WHR 0.97 (0.95-0.99) 0.82 (0.81-0.84) 
BMI  27.9 (26.8-29) 27.6 (27-28.3) 
 
 
The increase in AT associated with obesity can be deposited in various locations, 
but will mainly accumulate as WAT in various fat pads throughout the body.  WAT 
influences the physiological function of lipid and glucose metabolism along with 
possessing endocrine function (M.-J. Lee, Wu, & Fried, 2013).  Visceral adipose tissue 
(VAT) increases glucose uptake and metabolic activity in human subjects, in vivo, when 
compared to subcutaneous adipose tissue (ScAT)(Christen et al., 2010).  
Therefore, the type of diet as well as macronutrients and micronutrients consumed 
are important factors that could influence plasma apelin concentration at rest.  In 
addition, the amount of body fat and its location may also alter resting plasma apelin 
concentrations.  
Statement of Problem 
 The purposes of this study are to determine if baseline plasma apelin 
concentrations in apparently healthy, young adult human subjects are influenced by body 
composition, body fat distribution, and diet.  
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Objectives  
 Currently, there are no known “normal” baseline plasma apelin levels for healthy 
populations.  There has been research done on apelin levels in obese, diabetic, and 
several other special populations, but limited congruent data has been found in normal 
adult populations.  This study examined the baseline plasma apelin levels in normal, 
apparently healthy adult human subjects, along with three-day food logs and 
anthropometric measurements.   On the first visit, 7-site skinfold as well as SAD, BMI, 
and WHR were measured and used to determine the participants’ body fat composition 
and distribution.  Correlational analyses were conducted between %BF and plasma apelin 
concentration both at rest.  Also, with the analysis of the subjects’ diets, percentage of 
macronutrients and micronutrients were calculated in order to probe for relationships 
between consumption of specific macronutrients and micronutrients and apelin 
concentration.  The antioxidant concentrations of several micronutrients were also 
determined to ascertain if an association between these antioxidants intake influenced 
apelin concentration. 
Hypotheses 
1. A positive relationship will exist between body fat percentage and plasm aapelin 
concentration at rest. 
2. The location of fat (visceral) as determined by sagittal abdominal diameter (SAD) 
and waist-to-hip ration (WHR) will influence the plasma concentration of apelin 
at rest.  
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3. Individuals consuming a high fat diet should have a higher apelin concentration at 
rest. 
4. Individuals with low antioxidant consumption will have a higher apelin 
concentration at rest than those with adequate antioxidant consumption in their 
diets.  
Individuals with high zinc consumption will have a lower plasma apelin concentration 
than those with low zinc intake. 
Limitations 
 Diet for each subject was not controlled, but was indirectly monitored; each 
subject will be asked to maintain his or her normal diets throughout the study.  
They were given a3-day food log so they recorded their dietary intakes and were 
asked to reproduce their diets for each visit.  Subjects may not have reported their 
food intakes correctly; therefore, it is possible that the food logs may not reflect 
the exact amount of the macronutrients and micronutrients ingested.  
 Physical activity:  Subjects were told to maintain their normal activities 
throughout the study.   The pre-participation screening reflected their typical 
physical activity, but it is not the intention of this study to change their activity 
patterns.   
 Sleep: Subjects were asked to maintain their normal sleep patterns throughout the 
study. It is not known if sleep patterns influenced apelin and associated processes. 
 Alcohol consumption: Subjects were told not to ingest any alcohol at least 24 
hours prior to any experimental day.  
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 Eating behaviors (vegetarian/paleo/portion sizes): It will be unknown whether the 
subjects actually consumed all of the nutrients provided in the food log as well as 
if they correctly reported portions sizes.  
 Menstrual cycle was not assessed or monitored for the female subjects.  
 Genetics may be a factor and was not controlled.  
 The caloric balance of the subjects was not evaluated nor controlled. 
Delimitations 
 Apparently healthy subjects, aged 18-35, non-smokers and those not taking any 
medications or supplements known to affect fat and glucose metabolism were 
recruited. 
 Subjects were required to keep a three-day dietary record prior to both exercise 
sessions and the glucose load to assess dietary factor influences on apelin. 
 Subjects were required to discontinue any vitamin and antioxidant 
supplementation at least 2 weeks prior to any testing as this may influence 
markers of oxidative stress. 
 Subjects were not on any medications that might influence catecholamines and/or 
glucose, insulin or fat metabolism. 
 The subjects were non-smokers, not utilizing any tobacco products throughout the 
study. 
 No subject reported being ill or sick during their testing. 
 No subject reported any inflammation during their testing.  
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 Subjects reported to the laboratory in a post-absorptive state (at least 10 hours) 
and at the same time of day to avoid diurnal influences.  
 All measures of %BF, Height, Weight, WHR, WC, and SAD were determined by 
a single experimenter to minimize variability and utilized the same landmarks on 
all subjects. 
 All skinfolds were obtained by the same researcher, pinching the right side of the 
body at the various skin-fold sites at least 2 times.  
Variables 
Independent Variables: 
 Diet 
o Total kilocalories consumed 
o Macronutrient content 
o Antioxidant amount 
 Overweight/obese state 
o BMI (kg/m2) 
o Sagittal Abdominal Diameter (SAD) 
o % Body fat (7 site skin-fold) 
 Visceral vs. gynoid obesity 
o SAD 
o WC 
 Dependents Variables: 
 Apelin concentration at rest
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      CHAPTER II 
 
REVIEW OF LITERATURE 
 
 
Obesity and Body Fat Distribution 
Obesity can be characterized by the well-known consequence of increased fat 
mass, or increased amounts of AT.  AT is composed of fat cells, referred to as adipocytes 
and preadipocytes (adipocyte precursor cells) along with vasculature and nervous tissue 
(Avram, Avram, & James, 2005).  AT is generally labeled as either brown adipose tissue 
(BAT) or WAT.  Brown adipocytes are generally thought to be related to thermogenesis, 
via releasing cellular heat from food energy (Avram et al., 2005).  WAT primarily 
functions to store excess lipid and responds to activators to mobilize the storage form of 
TGs in response to deprivation of food or enhanced energy need (exercise) (McArdle et 
al., 2013).  WAT can be separated into intra-abdominal (VAT) and ScAT.  Intra-
abdominal fat is comprised of intraperitoneal and retroperitoneal fat, whereas ScAT can 
also be further divided into superficial and deep tissue layers (Avram et al., 2005).  Intra-
abdominal fat is mainly made up of intraperitoneal fat, which is further subdivided into 
omental (on stomach) or mesenteric (intestine) and epiploic (colon) fat tissue(Avram et 
al., 2005).   
 Due to WAT plasticity, adipocyte hypertrophy can expand the WAT during 
weight gain, which up-regulates the adipokines apelin and leptin as well as inflammatory 
cytokines (McArdle et al., 2013).  There also may be differences in endocrine function 
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based on location of AT.  VAT exhibits higher expression of plasminogen activator 
1(PAI-1) than subcutaneous adipocytes, possibly leading to increased blood clots or 
thrombosis in patients with T2D and obesity (Dusserre et al., 2000).  VAT also increases 
glucose uptake and metabolic activity in human subjects, in vivo, when compared to 
ScAT, possibly due to up-regulation of hexokinase (HK)-1 found in VAT-derived 
stromal vascular cells (SVCs) (Christen et al., 2010).   A negative consequence associated 
with increased visceral adiposity is the over-expression of pro-inflammatory cytokines 
including: interleukin-6 (IL-6), interleukin 8 (IL-8), monocyte chemoattractant protein-1 
(MCP-1), Regulated on Activation, Normal T Expressed and Secreted (RANTES) 
recently renamed chemokine ligand 5 (CCL5), macrophage inflammatory protein-1α 
(MIP-1α), and PAI-1, whereas leptin and interferon gamma-induced protein 10 (IP-10) 
are expressed more in ScAT(M.-J. Lee et al., 2013). 
Another negative consequence associated with obesity is oxidative stress, or a 
situation in which ROS accumulation occurs because the rate of production exceeds the 
rate of the antioxidant system’s scavenging ability exacerbating metabolic dysfunction 
and microvascular complications associated with hyperglycemic-induced diabetes (Scott 
& King, 2004).  It is important to look at the subject’s antioxidant intakes due to their 
ROS scavenging properties and ability to attenuate oxidative stress and ultimately 
decrease the chronic inflammation associated with obesity and its comorbidities.  ROS 
are also referred to as free radicals, a “species containing one or more unpaired electrons 
in their outer atomic orbital” (Nuttall, Kendall, & Martin, 1999).  This electron imbalance 
renders free radicals highly reactive and capable of interacting with many substances 
14	
such as lipids, proteins, DNA and carbohydrates.  The oxidation of these molecules can 
lead to disruption of protein structure, changes in cell membrane permeability, alteration 
of DNA transcription and influence carbohydrate storage, eventually causing a disruption 
of cell membranes leading to release of contents and cell death (apoptosis) (Nuttall et al., 
1999; Scott & King, 2004).  
Humans Studies: 
It is well documented that visceral adiposity/central obesity is a strong correlate to 
obesity-related disorders including hypertriglyceridemia, glucose intolerance, HTN, and 
IR (Jensen, 1989).  Increased expression of pro-inflammatory cytokines and IR-inducing 
factors lead to increased metabolic disturbances in humans with increased visceral 
adiposity, eliciting central obesity (Antuna-Puente, Feve, Fellahi, & Bastard, 2008; 
Dolinková et al., 2008; Fujioka, Matsuzawa, Tokunaga, & Tarui, 1987).  While it is well 
known that apelin has a positive relationship with obesity, more specifically it has shown 
relationships with BMI (Chen et al., 2014; Heinonen et al., 2005; Boucher, 2005, 
Sheibani, 2012).  However, to date, few if any studies have evaluated the relationship 
between visceral adiposity and plasma apelin.  It has been reported that subjects with 
central obesity and increased VAT accumulation have increased apelin levels, although 
measured via different methodology and utilizing diseased populations (Klöting, 2008, 
Schinzarí, 2014).  Several publications have reported WHR, WC and BMI as health risk, 
however these studies did not evaluate relationships between these factors and apelin 
concentration (Besse-Patin et al., 2014; Heinonen et al., 2009; N. P. E. Kadoglou et al., 
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2012; N. P. Kadoglou et al., 2013; Sheibani, Hanachi, & Refahiat, 2012).  Furthermore, 
we are not aware of any report that has compared SAD with apelin. 
Animal Studies: 
Due to the novelty of the apelinergic system, much of the current research has 
utilized animals, rather than human controls. In 2005, Boucher et al. demonstrated that 
the apelin gene (APLN) is expressed by both intra-abdominal and ScAT in mice 
(Boucher et al., 2005).  A more recent study reported that expression of APLN was 
higher in retroperitoneal WAT compared to subcutaneous WAT in rats (García-Díaz et 
al., 2007).  Garcia-Diaz et al. also reported that following 56 days of high-fat diet (HFD) 
feeding, rats demonstrated a higher expression of subcutaneous, but not retroperitoneal 
APLN gene expression(García-Díaz et al., 2007).  Adipogenesis can be inhibited by 
apelin/APJ via lymphatic and blood vessel integrity blocking the growth of lipid droplets 
in HFD-fed rats (Sawane, Mika Kajiya, Kentaro Kidoya, Hiroyasu Takagi, Masaya 
Muramatsu, Fumitaka Takakura, 2014).   
Diet: Macronutrients 
It is important to examine diet when investigating apelin due to the potential 
influence macronutrient and micronutrient intake may have on metabolism and adipokine 
expression.  The three main macronutrients considered building blocks of energy for the 
body’s physiological functioning are CHO, proteins and lipids.  The United States 
Department of Health and Human Services (HHS) and the U.S. Department of 
Agriculture (USDA) have published joint recommendations for daily energy intakes, 
stating that the diet should consist of 45-65% carbohydrates, 10-35% protein, and 20-
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35% fat.  This recommendation is based on their proposed 1,800-2,400 kilocalorie per 
day consumption by females and 2,400-3,000 kilocalorie per day allowance for males 
(U.S. Department of Agriculture and U.S. Department of Health and Human Services, 
2010).    
 
Table 4. Recommended Macronutrient Intakes (%). Source: U.S. Department of 
Agriculture, U.S. Department of Health and Human Services; www.dietaryguidelines.gov 
2010 
 
Recommended Macronutrient Intakes (%) 
 
  Carbohydrate 
(%) 
Protein (%) Fat (%) 
Adults (19 years and 
older) 
45-65% 10-35% 20-35% 
 
 
Table 5. Estimated Caloric Needs Per Day. Source: U.S. Department of Agriculture, U.S. 
Department of Health and Human Services; www.dietaryguidelines.gov 2010 
 
Estimated Caloric Needs Per Day  
 
Gender Sedentary Moderately Active Active
Males (19-30) 2,400-2,600 2,600-2,800 3,000
Female (19-30) 1,800-2,000 2,000-2,200 2,400
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Table 6.  Percentages of Energy from Protein, Carbohydrates and Fat by Gender and Age 
in the US. Source: USDA: NHANES “What We Eat in America” 2011-2012 
 
Percentages of Energy from Protein, Carbohydrates and Fat by Gender and Age 
in the US 
 
Gender Energ
y 
(kcal) 
Protein 
(% 
kcal) 
CHO 
(% 
kcal) 
Total 
Fat (% 
kcal) 
SFAs 
(% 
kcal) 
MUFAs 
(% 
kcal) 
PUFAs 
(% 
kcal) 
Males (20-29) 2764 
(74.5) 
16 (0.3) 48 
(0.8) 
33 (0.7) 11 
(0.3) 
12 (0.4) 8 (0.3) 
Females (20-
29) 
2019 
(41.6) 
15 (0.2) 51 
(0.6) 
33 (0.4) 11 
(0.2) 
12 (0.2) 8 (0.2) 
Males and 
Females (20 
and over) 
2191 
(15.6) 
16 (0.1) 49 
(0.3) 
33 (0.2) 11 
(0.1) 
12 (0.1) 8 (0.1) 
 
 
Similarly, the Institute of Medicine (IOM) has published Recommended Dietary 
Allowances (RDAs) and Acceptable Macronutrient Distribution Ranges (AMDRs) for 
macronutrients.  RDAs are recommended allotments of each macronutrient in grams per 
day representing the amount needed to meet the needs of almost all (97-98%) individuals.  
AMDR varies from RDA, representing an acceptable range of macronutrient intake 
associated with decreasing the risk of chronic disease and providing adequate intakes of 
essential nutrients (Institute of Medicine, 2005).  The RDA for carbohydrates is 130 
g/day, whereas the AMDR is 40-65 g/day. The AMDR for total fat is 20-35 g/day, 
however, no RDA is provided due to the increased risk for subjects on a high fat 
diet(Institute of Medicine, 2005). These recommendations for fat provide adequate intake 
for the use in structural membrane lipids, cell signaling, skin function and use as a 
precursor of eicosanoids (Institute of Medicine, 2005).  It is known that there is a 
relationship with saturated fats and increased risk for CVD(Alhazmi et al., 2012; Meza-
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Miranda et al., 2014; Peairs, Rankin, & Lee, 2011).  There are also concerns that trans-
fats increase low density lipoproteins(LDLs) and decrease high density 
lipoproteins(HDLs), increasing the risk of coronary heart disease (CHD) as reported by 
the CDC (Ogden, Carroll, Kit, & Flegal, 2014).   In association with CHOs and fats, it is 
important to maintain adequate protein intakes to build and remodel amino acids (AAs), 
function in enzymatic activity, and transport molecules and hormones.  In order to 
prevent deficiency syndromes, the AMDR recommendation for protein is 10-35 g/day 
and the RDA is 56 g/day for males and 46 g/day for females (Institute of Medicine, 
2005). 
 
Table 7. Nutritional Goals for Age-Gender Groups, Based on DRIs and Dietary 
Guidelines.  This table provides recommendations for macronutrients (USDA&DHHS, 
2010). AI = Adequate Intake, RDA=Recommended Dietary Allowances, AMDR = 
Acceptable Macronutrient Distribution Ranges  
 
Nutritional Goals for Age-Gender Groups, Based on DRIs and Dietary Guidelines  
 
Nutrients (units) Source of Goal Female (19-30) Male (19-30) 
Protein (g) RDA 46 56 
Protein (% kcal) AMDR 10-35% 10-35% 
Carbohydrate (g) RDA 130 130 
Carbohydrate (% kcal) AMDR 45-65 % 45-65% 
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Table 8. Macronutrient Intakes of Typical Americans. Source: USDA: NHANES “What 
We Eat in America” 2011-2012 
 
Macronutrient Intakes of Typical Americans 
 
Gender Energy (kcal) Protein (g) CHO (g) Total Fat (g) 
Males (20-29) 2764 (74.5) 102.9 (3.08) 332 (11.1) 102.3 (2.63) 
Females (20-29) 2019 (41.6) 72.1 (1.38) 255 (6.4) 75.5 (1.84) 
Males and Females 
(20 and over) 
2191 (15.6) 83.0 (0.75) 266 (2.4) 82.2 (0.77) 
 
 
Human Studies: 
These macronutrients exist in a delicate balance to supply the body with adequate 
energy supply during rest and work; imbalances, however may increase the risk for T2D 
(Alhazmi et al., 2012).  Meta-analyses done by Alhazmi and colleagues (2012) show that 
high CHO and high vegetable fat diets play a role in altering IR and thus, risk for T2D.  
Macronutrient intake, particularly high-CHO consumption has been correlated with an 
increase in risk for T2D, whereas diets high in vegetable fat show a decrease in risk for 
T2D in women.  Alhazmi’s group reported that the increased risk associated with high-
CHO diets was due to the high glycemic index/load, which may lead to increased insulin 
demand, elevated plasma glucose concentrations, and ultimately contributing to 
pancreatic failure and glucose intolerance, the pathophysiological hallmarks for T2D.  It 
has also been reported that females consuming diets high in vegetable fats may see a 
decreased risk for T2D and increased insulin sensitivity through improvement in lipid 
profiles and better glycemic control in diabetics (Alhazmi et al., 2012). 
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Animal Studies: 
Mei et al. demonstrated that a HFD (>37% fat in the diet) increased lipogenesis 
and elicited IR, and adding 5% CHO to this HFD significantly worsened HFD-induced 
oxidative stress, thus exacerbating IR and ectopic fat accumulation in mice.  The addition 
of 10% CHO to this HFD induced maximal IR.  This study suggests that CHOs are not 
necessary for HFD-induced IR to occur, possibly due to hepatic gluconeogenesis, but 
addition of CHOs to a HFD will dramatically aggravate IR induced by a HFD (Mei et al., 
2014).  In lean Zucker rats, postprandial oxidative stress was exhibited after eating a 
meal, while overweight and obese individuals experienced a constant state of low-grade 
inflammation and oxidative stress.   
Diet: Micronutrients 
While macronutrient intake is an important mediating factor in postprandial 
oxidative stress, micronutrient, specifically, antioxidant intake may play a substantial role 
in redox reactions and oxidative stress.  It is suggested by the Food and Nutrition Board 
(FNB) of the IOM that the RDA for vitamin C is 90 mg/day for males and 75 mg/day for 
women, 900 mcg/day for men and 700 mcg/day for women in terms of vitamin A, and 15 
mg/day for both genders for vitamin E.  The RDAs listed for vitamin A are based on the 
amount of intake necessary to ensure adequate storage to support normal physiological 
functions. Both vitamin C and vitamin E are known antioxidants which can help reduce 
oxidative stress(Institute of Medicine, 2005).  
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Table 9. Nutritional Goals for Age-Gender Groups Based on DRIs and Dietary 
Guidelines.  This table provides recommendations for micronutrients. Source: U.S. 
Department of Agriculture, U.S. Department of Health and Human Services; 
www.dietaryguidelines.gov 2010 
 
Nutritional Goals for Age-Gender Groups, Based on DRIs and Dietary 
Guidelines  
 
Micronutrient 
(units) 
Source of Goal Female (19-30) Male (19-30) 
Zinc (mg) RDA 8 11
Vitamin A (mcg 
RAE) 
RDA 700 900
Vitamin E (mg 
AT) 
RDA 15 15
Vitamin C (mg) RDA 75 90
 
 
Table 10. Typical Micronutrient Intakes of Americans. Source: USDA: NHANES “What 
We Eat in America” 2011-2012 
 
Typical Micronutrient Intakes of Americans 
 
Gender Retinol  
(ug) 
Vitamin A 
(RAE)  
(ug) 
Beta-
Carotene  
(ug) 
Vitamin C 
(mg) 
Vitamin E 
(alpha-
tocopherol
) (mg) 
Zinc 
(mg) 
Males 
(20-29) 
458 
(41.5) 
612 (52.4) 1678 (191.4) 98.3 
(10.72) 
10.2 
(0.35) 
14.0 
(0.38) 
Females 
(20-29) 
389 
(22.8) 
593 (36.3) 2192 (254.1) 83.0 
(6.71) 
8.0 
(0.38) 
10.0 
(0.26) 
Males 
and 
Females 
(>20) 
444 
(24.6) 
674 (38.0) 2500 (181.7) 84.8 
(4.10) 
9.0 
(0.16) 
11.5 
(0.15) 
 
The main source of ascorbic acid (vitamin C) and carotenoids (vitamin A) are 
through dietary fruit and vegetable consumption, which are also a source of tocopherols 
(vitamin E).  Micronutrient deficiency is an important issue because nationwide only 
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about 9% of Americans eat the recommended daily servings of fruits (5 servings) and 
vegetables (4 servings); similarly, the NHANES reports the typical American diet is 
deficient in vitamin E intake (Ames, Shigenaga, & Hagen, 2014).   Vitamin E 
(tocopherols) can be found in nuts, vegetables, fruits, oil, and seeds; vitamin C (ascorbic 
acid) can be found in most citrus fruits and various vegetables; carotenoids are also found 
in fruits, vegetables and seaweeds (Osawa & Kato, 2005).   
 Antioxidants can be classified into three categories: metal ion binding proteins, 
intracellular antioxidant enzymes, and extracellular antioxidants.  Certain antioxidants are 
considered metal binding and decrease the hydroxyl radical production such as 
transferrin, ceruloplasmin and albumin.  There are also intracellular and extracellular 
antioxidant enzymes.  Intracellular antioxidants include superoxide dismutase, catalase 
and selenium-dependent glutathione peroxidase, which are implicated in trapping free-
radical by-products of cellular metabolism as enzymatic regulators.  In addition, 
glutathione is an important non-enzymatic intracellular antioxidant, which helps donate a 
hydrogen ion to help reduce ROS.  Antioxidants such as α-tocopherol, β-carotene, and 
vitamin C are considered non-enzymatic substances and help prevent or quench some of 
the ROS to lesser active molecules.  In conjunction with the enzymes, a hydrogen donor 
is needed, often obtained from the molecule glutathione (GSH) and is returned to the 
oxidized form, glutathione disulfide (GSSG) with a NADPH donor via co-enzyme 
glutathione reductase.  Thus, a major intracellular regulator of oxidative stress is the 
glutathione (thiol) reaction, which is also related to the reestablishment of both vitamin C 
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and E to their reduced forms (Ames et al., 2014; Antoniades, Tousoulis, Tentolouris, 
Toutouzas, & Stefanadis, 2003) 
Human Studies: 
 
 In a recent study, it was suggested that micronutrient deficiencies have an effect 
on angiogenesis and chronic inflammation, also showing correlations to increased obesity 
rates among impoverished communities (Olga P García, Long, & Rosado, 2009).  Low 
levels of vitamin C and vitamin E:lipids ratio have been correlated with obesity and 
overall low-grade systemic inflammation (Olga Patricia García et al., 2013).  
Observational studies suggest that vitamin A and/or C may be able to restore endothelial 
function and possibly have anti-inflammatory and anti-thrombotic properties; although, 
randomized control trials (RCTs) have not confirmed their role in inhibiting 
atherosclerosis (Antoniades et al., 2003).  Obese and overweight children have lower 
concentrations of vitamin A and elevated triglycerides along with increases in C-reactive 
protein (CrP), whereas low vitamin E concentrations were associated with decreased 
glucose and triglycerides, along with higher LDLs (Olga Patricia García et al., 2013).  
Garcia et al. (2013) also reported that zinc deficiency was correlated with increased 
insulin resistance(Olga Patricia García et al., 2013).  In 2007, Garcia-Diaz et al. showed 
that apelin gene expression was maintained at elevated levels even when vitamin C 
supplementation resulted in a decrease in adiposity and other obesity markers (García-
Díaz et al., 2007). Therefore, more work is needed to understand the influence of vitamin 
C on apelin concentration. 
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Table 11. Percentage of Americans with Inadequate Dietary Intakes Based on EARs. 
Source: What We Eat in America, NHANES 2001-2002 
 
Percentage of Americans with Inadequate Dietary Intakes Based on 
EARs 
 
Nutrient Percent 
Vitamin A 44% 
Vitamin C 31% 
Vitamin E 93% 
Zinc 12% 
 
 
 A recent review by Garcia et al. (2009) reported that vitamin A deficiencies have 
been linked to elevated weight, BMI, and hip circumferences in overweight and obese 
subjects(Olga P García et al., 2009).  Plasma retinol levels have been used as an indicator 
of vitamin A deficiencies and have been negatively correlated with overweight and obese 
children, as well as increased insulin resistance in morbidly obese adults (Olga P García 
et al., 2009). Dietary deficits of vitamin A intake have also been implicated in the 
increased incidence of obesity among humans, whereas retinoic acid (RA) 
supplementation was shown to decrease body weight, body fat, retroperitoneal WAT, and 
adipocyte size in mice(Olga P García et al., 2009).  Similarly, Vaughan et al. (2007) 
reported a significant correlation between vitamin A deficiency and an increased 
incidence of obesity in Native American adults (Vaughan, Benyshek, & Martin, 1997).  
Several pathways have been proposed in terms of how RA might inhibit adipogenesis.  
Menendez, et al. suggested that RA and vitamin D3 may exhibit a direct inhibitory effect 
on the secretion of leptin and pro-inflammatory cytokines from adipose tissue in vivo, 
which may also play an important role in regulation of food intake, energy expenditure 
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and body composition (Menendez et al., 2001).  Another possible link between obesity 
and insulin resistance may be through retinol-binding protein (RBP4), a cytokine shown 
to be secreted from AT and the liver, and has been associated with increased BMI, IR, 
dyslipidemia, HTN, and visceral adiposity.  It was proposed that RBP4 is up-regulated in 
response to decreased expression of glucose transporter (GLUT 4) within AT, which was 
suggested to lead to IR (D. F. Garcia-Diaz, J. Campion, F. I. Milagro, L. Paternain, 
2009). 
 
Table 12.  Typical American Diets vs. Recommended Intake Levels. Source: U.S. 
Department of Agriculture, U.S. Department of Health and Human Services; 
www.dietaryguidelines.gov 2010 
 
Typical American Diets vs. Recommended Intake Levels 
 
Food Type Usual intake as % of goal or 
limit 
Whole Grains 15% 
Vegetables 59% 
Fruits 42% 
Oils 61% 
Fiber 40% 
Calories from Solid fats/added 
sugars 
280% 
Refined Grains 200% 
Sodium 149% 
Saturated Fat 110% 
 
 Vitamin C is considered a potent water soluble, natural antioxidant in terms of its 
ROS scavenging properties within the cytoplasm and its NF-κB-mediated anti-
inflammatory properties, as well as its role in regeneration of oxidized vitamin E to 
reduced vitamin E and conservation of β-carotene during times of oxidative stress 
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(Antoniades et al., 2003; Garcia-Diaz et al., 2011; Pedraza, Bo, & Golde, 2002).  Vitamin 
C has been associated with a down-regulation of proteins implicated in several metabolic 
pathways: the pentose phosphate cycle, tricarboxilic-acid cycle, and progesterone and 
isoprenoid biosynthesis.  Vitamin C has been shown to influence stimulation of 
adipogenesis, suggesting a link with these pathways and vitamin C (Campión, Milagro, 
Fernández, & Martínez, 2006).  Campion and colleagues (2006) reported that vitamin C 
supplementation (75 mg/kg rat) in conjunction with a high fat diet decreased body weight 
and fat content (without affecting food intake) in rats, compared to a similar high fat, 
hypercaloric Western diet, without vitamin C.  Thus, vitamin C demonstrated an anti-
obesity protective property in rats, however this needs to be substantiated in humans 
(Campión et al., 2006).  Pedraza and colleagues (2002) incubated cells with 
dehydroascorbic acid (DHA), the oxidized form of vitamin C, which may inhibit the 
TNF-α mediated activation of NF-κB- inducing kinase (NIK) and IkB (IKKβ) 
independent of the p38 MAP kinase pathway, influencing the inflammatory, neoplastic, 
and apoptotic cell processes via tumor necrosis factor-α(TNF-α) mediated NF-κB 
inhibition (Pedraza et al., 2002).  Vitamin C treatment was associated with decreased 
body weight gain, and lower plasma leptin levels along with down-regulation of apelin 
gene expression in adipose tissue of rats (García-Díaz et al., 2007). 
 Vitamin E is partially regulated by vitamin C-mediated reduction of the oxidized 
form of vitamin E (the vitamin E radical), creating a synergistic effect between vitamin C 
and vitamin E (Nuttall et al., 1999).  In terms of vitamin E, its primary component, α-
tocopherol, is implicated in the antioxidant protective properties of oxidative 
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modification of lipids such as low-density lipoproteins (LDLs), whereas γ-tocopherol is 
associated with scavenging peroxynitrite-derived free radicals in the natural diet 
(Antoniades et al., 2003; Opie, 1997).  Vitamin E is considered “the major lipid-soluble 
antioxidant” preventing the development of lipid hydroperoxides from PUFAs, and is 
found within LDL and all membranes, preventing lipid peroxidation (Antoniades et al., 
2003).Although it is difficult to demonstrate vitamin E deficiency, since it is stored 
within lipids, dietary research has noted that vitamin E consumption is inadequate in most 
American diets(U.S. Department of Agriculture and U.S. Department of Health and 
Human Services, 2010). Therefore, it would be informative to understand if vitamin E 
and vitamin C consumption may influence apelin concentration and its response to 
stressors that theoretically should increase its release.  
 Olga et al. (2009) reported that low zinc intake and plasma zinc concentrations 
correlated with an increased incidence of obesity, specifically central adiposity and its 
associated comorbidities including heart disease and T2D.  A possible mechanism by 
which a marginal zinc deficiency may alter adipogenesis is through a reduction in leptin 
concentration, possibly leading to increased risk for obesity (García-Díaz et al., 2007).  In 
obese and overweight individuals, insufficient zinc intake increased oxidative stress and 
inflammatory responses associated with decreased superoxide dismutase activity and 
glutathione peroxidase, leading to reduced lean body mass and increased body fat (Olga P 
García et al., 2009).  Therefore, adequate zinc intake within the diet may help attenuate 
some of the associated declines in enzymatic oxidative stress control and thus may reduce 
obesity. 
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Animal Studies: 
 
Apelin has been implicated in the ROS scavenging of H2O2, considered a primary 
cause of insulin resistance in which nitric oxide (NOS)-stimulated hypothalamic 
hyperglycemia increases mitochondrial ROS (mROS) in the hypothalamus, thus initiating 
peripheral hyperinsulinemia, and increased glucose storage (Drougard et al., 2014; 
Fisher-Wellman & Neufer, 2012).  Trolox (water-soluble vitamin E analog) has been 
shown to completely inhibit several processes including: apelin-induced hyperglycemia, 
increased H2O2 release from the hypothalamus, as well as the stimulation of hepatic 
glycogenolysis in apelin-injected mice (Drougard et al., 2014).  Apelin has also been 
shown to activate glucose 6-phosphatase (G6Pase) enzymatic pathway, which implicates 
apelin’s role in stimulation of glycogenolysis and gluconeogenesis in the liver of apelin-
treated mice (Drougard et al., 2014).Furthermore, they also reported that Trolox and 
F13A (APJ antagonist) inhibited this apelin-induced stimulation of glycogenolysis and 
gluconeogenesis within the liver of mice, as well as completely blocked apelin-induced 
hyperglycemia in HFD mice (Drougard et al., 2014 ). 
 Garcia-Diaz et al. (2011) showed that the antioxidant vitamin C decreased 
macrophage induced inflammation via inhibition of NO and down-regulation of MCP-1 
and apelin in mice preadipocytes.  These results suggested that vitamin C may provide a 
pathway to improve insulin resistance not only through its control of oxidative stress and 
inflammation but also through apelin(Garcia-Diaz et al., 2011).   Additional information 
regarding micronutrient influence on apelin regulation is limited. This emphasizes the 
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importance of analyzing diets and antioxidant consumption when analyzing baseline 
plasma apelin levels of normal, apparently healthy human populations. 
Apelin 
 Apelin, a recently discovered 36 amino acid peptide, located on the Xq25-26.1 
chromosome, is a cognate ligand for the G-protein coupled receptor (GCPR) referred to 
as APJ (Beltowski, 2006; Tatemoto et al., 1998).  Tatemoto et al. (1998), first isolated 
apelin using bovine stomach extracts in 1998.  Apelin’s precursor, referred to as 
preproapelin, is comprised of a 77 amino acid sequence, from which several mature 
forms of the apelin peptide emerge, encoded by the gene APLN.  The most abundant 
form of apelin, apelin-36, is thought to be a “mature form” of the apelin peptide, with 
apelin-12, apelin-17, apelin-13, and [pyr]-13 apelin to be less abundant but more potent 
(O’Carroll, Lolait, Harris, & Pope, 2013). 
Human Studies: 
 Although research has expanded in regards to apelin, many of the studies are 
being done in rodents rather than human subjects.  In human studies, much of the 
literature is conflicting, thus, it is important that apelin concentrations in normal, healthy, 
young controls are established (see Table 13).  Researchers have shown apelin gene 
expression in the brain and peripheral tissues in the heart, spleen and liver of humans.  
Preproapelin was discovered in various regions of the brain including the caudate 
nucleus, thalamus, hypothalamus, hippocampus, midbrain, basal forebrain and frontal 
cortex (D. K. Lee et al., 2000).	 	
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Table 13. Previous Studies Reporting Plasma Apelin Concentrations in Healthy Human 
Subjects. 
	
Previous Studies Reporting Plasma Apelin Concentrations in Healthy Human 
Subjects 
 
Study Year Apelin 
Concentration 
(ng/ml) ± SE 
Kit Origin Procedure/Kit 
Utilized 
Zhen et al.  2013 0.1292 ± 0.0203 EIA Burlingame, 
CA 
Phoenix 
Pharmaceuticals: 
Apelin-12 HRMB 
Mesmin et 
al.  
2010 0.369 ± 0.08 EIA Strasbourg, 
France 
Phoenix 
Pharmaceuticals: 
Apelin-12 HRMB 
Baso 2007 0.738±0.186 EIA Belmont, CA Phoenix 
Pharmaceuticals: 
Apelin-12 HRMB 
Castan-
Laurell et al.  
2008 0.272 ± 0.02 EIA Burlingame, 
CA 
Phoenix 
Pharmaceuticals: 
Apelin-12 HRMB 
Soriguer 2009 1.12±0.51 EIA Belmont, CA Phoenix 
Pharmaceuticals: 
Serum Apelin-12 
Heinonen 2009 0.174±0.014 EIA Belmont, CA Phoenix 
Pharmaceuticals: 
Apelin-12 HRMB 
Alexiadou et 
al.  
2012 1.89 ± 0.14 EIA CA Phoenix 
Pharmaceuticals: 
Apelin-12 HRMB 
Kadoglou et 
al.  
2012 0.213 ± 0.114 EIA Belmont, CA Phoenix 
Pharmaceuticals: 
Apelin-12 HRMB 
Ba et al. 2013 1.13±0.55  EIA Belmont, CA Phoenix 
Pharmaceuticals: 
Serum Apelin-12 
Papadopoulo
s et al.  
2013 0.315 ± 0.147 RIA Burlingame, 
CA 
Phoenix 
Pharmaceuticals: 
Apelin-12 HRMB 
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Animal Studies: 
 Similar to humans, rats express preproapelin in the frontal cortex, cortex striatum, 
midbrain, hippocampus, medulla, pons, and cerebellum of the brain, along with several 
peripheral tissues including pituitary, olfactory tubercle, septum, adrenal, vas deferens, 
testis, intestines and kidneys, as well as in rat fetuses (D. K. Lee et al., 2000). 
 Apelin, primarily secreted from adipocytes, is considered a novel adipokine, 
recently discovered, with little knowledge of its pathophysiological implications 
(Daviaud et al., 2006).  Adipocytes, or fat cells have been shown to produce both apelin 
and the APJ (Langelaan et al., 2009).  AT possesses endocrine function and has been 
implicated in communicating to other cells to regulate several factors including 
substances called adipokines, also referred to as adipocytokines(Schutte et al., 2010).   
Apelin and Exercise 
Kadoglou et al. (2012) suggested that along with other adipokines including 
visfatin and adiponectin, apelin is increased with physical activity lifestyle modifications 
among patients diagnosed with T2D.  However, the influence in healthy young 
individuals has not yet been adequately determined. 
APJ 
 APJ, gene symbol APLNR is known as a GCPR which sense extracellular 
molecules and act to achieve cellular responses via signal transduction.  APJ acts as the 
receptor for the cognate ligand, apelin, and thus far has been found in the brain and 
peripheral tissues in both rodents and humans.APJ immunoreactivity staining showed 
less apelin expression in cardiomyocytes, glial cells of the brain, and vascular smooth 
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muscle cells in humans (Bełtowski, 2006; Langelaan et al., 2009).  Research suggests that 
APJ expression is mediated by the severity of IR.  Rodent studies showed decreased APJ 
expression in insulin-resistant mouse skeletal muscle and that APJ expression was not 
affected by acute feeding/refeeding (Castan-Laurell, Vítkova, Daviaud, Dray, 
Kováčiková, et al., 2008; Dray et al., 2008).   However, there may be differences in APJ 
expression and IR for the various tissues in rodents and humans (Dray et al., 2010) 
Increased expression of the APJ gene occurs during times of acute and repeated stress, 
which was suggested to be related to glucocorticoid dependent mechanisms (O’Carroll et 
al., 2013).  This is important in terms of obesity due to the chronic state of low-grade 
inflammation and oxidative stress exhibited with obesity and its comorbidities.  APJ 
shows significant similarities to the angiotensin receptor, angiotensin II type 1 (AT1), 
~30% homology to the angiotensin receptor, although the APJ receptor did not show 
affinity for angiotensin II (D. K. Lee et al., 2000).   
To date, only one metabolic pathway has been found for apelin involving the 
zinc-containing carboxypeptidase, angiotensin-converting enzyme-2 (ACE2), which is 
involved in the conversion of angiotensin I to II into active forms found primarily in the 
endothelial vasculature of the heart, kidney and testis (Bełtowski, 2006).  This is 
important in terms of the antioxidant role in apelin expression because the only known 
pathway involves ACE2, which is zinc-dependent. Therefore, we determined if the zinc 
consumption in our subjects was within the normal range as an index of its role in 
controlling enzymatic function related to oxidative stress and apelin expression. 
Additionally, we ascertained if there is a relationship between zinc consumption, total 
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antioxidant intake, total kilocalories consumed, percentages of macronutrients, body fat 
distribution, and body composition in relation to apelin at rest and in response to exercise 
and glucose-induced stress.  
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CHAPTER III 
METHODS 
 
 
Subjects 
 Subjects for this study were recruited on a volunteer basis.  During the first visit 
the subjects reviewed and signed a written consent form according to University of North 
Carolina at Greensboro IRB standards as well as underwent a pre-participation screening 
(Appendix A/B).   Fifteen subjects were recruited, however this data is part of a larger 
study, and therefore three subjects (2 males, 1 female) were not included due to abnormal 
glucose responses during the 54g glucose challenge.  The reported values include twelve 
(n=8 M, n=7 F) apparently healthy, non-obese (skinfold & BMI) subjects between the 
ages of 18-35 and not using tobacco products or taking any medications or supplements 
that may alter antioxidant concentration, metabolism, blood glucose and/or insulin were 
recruited.  Both male and female subjects were recruited in order to get a general baseline 
plasma apelin level in young, apparently healthy individuals. 
Study Design 
Inclusion/Exclusion Criteria: 
 Prior to acceptance into the study, potential participants attended a screening and 
consenting session in which potential medical, cardiovascular, physical activity and other 
possible confounders that may exist were addressed (Appendix A/B).  Those excluded 
from the study included tobacco users of all forms and pregnant women as well as obese 
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individuals (BMI and %BF via skinfold analysis> 2 SD above norm for age category) 
and individuals who were not otherwise apparently healthy. Potential subjects were 
screened using American College of Sports Medicine (ACSM) CV risk factor assessment 
(ACSM Pre-Participation Health Screening – Appendix A); those meeting ≥ 2 CV risk 
factors were excluded from the study.  Other exclusion criteria included those on 
medications and supplements known to influence metabolism, oxidative stress, and/or 
inflammation to prevent confounding outcome measures (Adapted Health History 
Questionnaire - Appendix B).   Those included in the study were within the specified age 
range and meet all inclusion criteria to achieve a healthy population. 
Screening/Consenting Session (Visit 1) 
Before beginning the study, subjects attended a screening for health history and 
physical activity for use as part of inclusion and exclusion criteria (Appendix A/B).  If 
they met all inclusion criteria and no exclusion criteria, they were asked to participate as 
a subject and read and sign the institutional review board (IRB) approved informed 
consent form.  At this time, they were given ample time to ask questions and were 
informed of potential risks and benefits.  Once the subject signed the informed consent 
form and completed screening, they were considered “active subjects.” At this time the 
subjects’ resting measures were recorded including heart rate, blood pressure, height and 
weight.  These measures were used as inclusion/exclusion criteria, excluding subjects 
who did not exhibit normotensive blood pressure and those considered obese via BMI 
(kg/m2). During this visit, the subject was also informed about their involvement and 
provided a study timeline, detailing their requirements, screening/consenting and all 
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interventions and their responsibilities.  The subjects were given a three-day food log, 
instructed on how to properly input their diets, in which they recorded the specific food 
they consumed, amount of food, time consumed, how the food was prepared and caloric 
content if known.  If subject had food labels, the subject was asked to submit the labels to 
the researcher for analysis.  The macronutrient and micronutrient content was analyzed 
using USDA Food Nutrient Database, http://fnic.nal.usda.gov/food-composition/usda-
nutrient-data-laboratory.  The subjects were provided copies of their first 3-day food log 
and upon each visit, the participant was told to reproduce their originally recorded diets 
as consistently as possible for the consecutive visits. Upon receipt of each food log, the 
subject was prompted to ensure all cooking methods and possible added sources of 
nutrients were properly understood.  Notes were made in regards to their measurement 
techniques as well as any condiments or cooking methods they may use. The 
macronutrients were converted to kilocalories using the standard conversions of 4 kcal 
per gram of CHO and Protein and 9 kcal per gram of fat (Dietary Reference Intakes: 
Macronutrients, 2005) .  The average was taken from each visit and then compared 
across visits.  There were no significant differences between visits; therefore the data was 
collapsed across visits, to provide an average kCal intake per subject for each 
macronutrient. The same was done for vitamin A, vitamin C, vitamin E, and %RDA 
TAC.   
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Subject Testing 
The subjects were asked to arrive at the laboratory in the morning fasted in a post-
absorptive state (6-10 hours) without consuming caffeine, alcohol or any contraindicated 
substance.  The subjects arrived rested, not having exercised within the past 24 hours 
prior to the visit. 
During the first visit, the subject was weighed (Seca scale) to the nearest .1 kg and 
height was measured using a stadiometer to the nearest 0.1 cm to determine BMI (kg/m2). 
The equation for calculating BMI is as follows: BMI (kg/m2) = body mass (kg)/height 
(m2).  To determine height, the subject was asked to remove their shoes, stand straight up 
with heels together, take a deep breath and hold it while looking straight ahead with their 
head level(National Heart Lung and Blood Institute & National Institutes of Health (NIH) 
National Heart, Lung, and Blood Institute, 1998). Heart rate was attained via brachial 
artery and blood pressure using an auscultatory cuff, measured on the right side of the 
body to assure participants remained within the inclusion criteria as well as to establish 
baseline measures. % BF was calculated using 7-site skinfold (chest, tricep, axilla, 
subscapular, abdominal, suprailium, thigh) (See Appendix G for location and direction of 
each skin fold site) using a Harpenden caliper that provides a constant pressure of 
~10g/mm2.  Each fold was measured to the nearest 0.5 mm on the right side of the body, 
with each measurement within 2 mm or a third reading was taken until at least two 
measures were within 2 mm of each other to ensure reliability and validity.  The skinfold 
was grasped firmly between the thumb and index finger of the left hand, facing up the 
jaws of the caliper were placed 1 cm below the pinch (Ehrman, 2010; Maud &Foster, 
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2006).The average of each skinfold site was summed and put into the Jackson and 
Pollock body density equation, based on the fact that the majority of subjects were 
Caucasian(Jackson & Pollock, 1978).  Using these equations, the subjects’ lean body 
mass was also calculated and used in correlational analysis.  The subjects’ body density 
was then used to calculate % body fat using both the Siri and Brozek equations. 
Body Density:  
 
Males: (7) = 1.112 - (0.00043499 x 7) + (0.00000055 x (7)2) - (0.00028826 x 
age) 
 
Females: Db (7) = 1.097 - (0.00046971 x 7) + (0.00000056 x (7)2) – 
 
(0.00012828 x age) 
 
% Fat: Siri: 457/BD-414/2 (Ehrman, 2010; Siri, 1956)(Siri, 1956) 
% Fat Brozek: 495/BD-450 (Brozek, J; Grande, F; Anderson, 1963; Ehrman, 
2010) 
Waist circumference, measured at the natural waist (around the smallest area of 
the abdomen), was measured using a tension-controlled tape.  If measurements were 
within ¼” of each other, the average was reported.  If the variance was greater than ¼” 
measurements were repeated until measurements were within ¼ inch of each other. This 
measure was used as a correlate for visceral adiposity (Ehrman, 2010).  Hip 
circumference, measured around the largest area of the buttocks was used in conjunction 
with the waist circumference (WC) to calculate the WHR, by dividing waist 
circumference by hip circumference (Ehrman, 2010; Gregory Byron Dwyer; Shala E. 
Davis; American College of Sports Medicine (ACSM) Staff, 2008).Hip circumference 
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measurements were taken in duplicate and averaged.  SAD was measured using a caliper 
to the nearest 0.1 cm at the umbilicus and between the 4th and 5th lumbar vertebrae on the 
exhale; two separate measurements were taken and then averaged(U. Risérus, De Faire, 
Berglund, & Hellénius, 2010a).  SAD was measured in conjunction with the typical waist 
circumference and waist to hip ratio to ascertain a more comprehensive estimation of the 
subjects’ visceral body fat distribution.  
VO2Max -Treadmill GXT -Condition A: 
 The subjects arrived rested, not having exercised within the past 24 hours prior to 
the visit. Weight was taken on SECA scale, Polar heart rate monitor was put on, and the 
subject rested for 15 minutes. During this time the researcher inquired about the subjects’ 
physical activity including their typical mile pace to determine the speed at which to 
begin the graded exercise test (GXT). 
The subject then had their blood drawn from an antecubital vein into EDTA tubes 
(lavender top); following a 15 minute rest period. Participants were strongly encouraged 
to drink water to help maintain plasma volume. 
At least 5 min post blood draw, the exercise testing began.  Condition A consisted 
of a graded maximal treadmill test, following Dr. Goldfarb’s unpublished protocol in 
order to determine the subject’s maximal oxygen consumption (VO2max) running on a 
Quinton Q-Stress Treadmill; This protocol gave the subject a 3-5 minute warm-up based 
on the subject’s comments and heart rate. The speed of the treadmill was gradually 
increased during this time to elicit a heart rate between 120-135beats per minute (bpm).  
At this time the subject was then asked to place the mouth piece and nose clips on and 
40	
oxygen uptake was analyzed using a one-way valve via PARVO Medics TrueOne 2400 
Metabolic Measurement System calibrated to known gases prior to the test. The treadmill 
speed was increased each minute to bring the subjects’ heart rate up to 135-145 bpm. The 
subject indicated ratings of perceived exertion (RPE) and heart rate (HR), ventilation 
(VE) and oxygen consumption (VO2) were continuously monitored throughout the 
protocol.  Once they reached the proper heart rate the grade of the treadmill increased 
2.5% each minute until the subject reached VO2 max, or they indicated they wanted to 
stop. The researcher always asked if it was okay to increase the workload, which was 
increased every minute until the participant requested termination or the researcher saw a 
plateau in VO2.  The subject indicated their RPE on a chart by pointing to the number (6-
20) in the last 15 seconds of each workload. The researcher also recorded respiratory 
exchange ratio (RER), VO2, carbon dioxide output (VCO2), and VE throughout the test. 
The test was terminated if the subject requested to stop due to volitional fatigue or 
their VO2 plateaued or there were any abnormal occurrences.  To achieve a true VO2max, 
three of the four criteria must have been met: 95% age-predicted maximum HR, RER 
>1.1, VO2plateau, or RPE >19.The VO2max test is considered vigorous intensity and 
thus, should have elicited an increase in blood glucose, causing a rise in insulin, which 
may have altered plasma apelin concentration.  The rise in blood glucose was likely 
caused by a catecholamine response to high intensity exercise as well as glucagon 
increasing, allowing glucose to dump into the blood due to increased carbohydrate 
requirements, as carbohydrate provides more energy more rapidly at higher intensity of 
exercise. Water was provided prior, post, and with the one hour following the GXT to 
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ensure proper hydration.  Blood was also taken immediately after the VO2max test but 
was not utilized for this aspect of the study as this aspect focused on resting blood apelin. 
As noted before, the subjects participated in three treatment conditions as part of a 
larger study, however only resting, pre-visit values will be reported.  These three 
conditions were semi-randomized in that the subjects were randomly assigned to either 
Condition A (VO2max) or Condition C (54 g glucose feeding) first.  It was imperative 
that the VO2max test occurred prior to the submaximal run, in order to provide a 
reference for the 70-75% submaximal treadmill run.  Subjects either completed the study 
conditions as follows: Condition A, B, C; C, A, B; or A, C, B.  
Blood Timing and Handling 
 Prior to intervention, following a≥15-minute rest period in the laboratory in order 
to obtain a baseline sample at rest in a fasted state at visits A, B and C.  Blood samples 
were obtained from the antecubital vein using 7 mL EDTA tubes (lavender top) and 
immediately processed then centrifuged.  EDTA, a substances used to prevent clotting via 
Calcium binding, was used because all previous studies have utilized EDTA tubes except 
4 (2 did not specify, 2 used serum) as specified in the protocol for Phoenix 
Pharmaceuticals].   The remaining blood was placed in an ice bucket and immediately 
transported and centrifuged in a Beckman-Coulter Allegra swinging bucket centrifuge or 
a Beckman-Coulter Avanti J-E centrifuge for 10 minutes at 3,000 revolutions per minute 
(RPM) at 4° C to obtain plasma.  The plasma samples were then aliquoted into plastic 
microtubes (to prevent freeze thawing of samples for different assays) and placed in an 
Ultima II freezer at -80°C for storage until analysis.   
42	
Blood Sampling & Assays: 
 
Plasma apelin levels were measured using the ELISA immunoassay (EK-057-15) 
procedures described (Phoenix Pharmaceuticals) and measured at 450 nanometers (nm) 
using a BIO-TEK INSTRUMENTS PowerWave x340 KC Junior Microplate reader in 
duplicate.  If the duplicates were not within 2 standard deviations from each other, the 
sample was measured again.  The average of the two closest values was utilized to 
determine apelin concentration.  
Statistical Analysis 
Using the G*Power application, a sample size of n=11 was deemed appropriate 
for this study, yielding a power of ≥ 0.80.  This power analysis was based on an effect 
size of r=0.7 and α=0.05 and a population mean and standard deviation of 0.438±0.191 
ng/ml, determined from healthy controls in 7 preceding studies.  In addition each 
subject’s caloric balance was calculated using the Harris-Benedict equation to determine 
and compared to plasma apelin concentrations. 
The data was analyzed using IBM SPSS using repeated-measures ANOVA 
(RMANOVA) within subject for each variable as well as nutrient data and plasma apelin 
concentration for each visit in order to compare across conditions to determine if there 
are variations for each subject. When no variations were found, the diets were collapsed 
across time points and reported as an average.   
In addition, correlational analysis compared apelin to each of the outcome 
variables, using SPSS Pearson Correlational Analysis.  If Mauchly’s test for sphericity 
found that the data was not equally distributed, a Spearman’s Correlational Analysis was 
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run.  In addition, all measures were compared by gender with a simple t-test, to determine 
if there were gender differences.  The significance level was set at 0.05 for all data 
analysis.
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CHAPTER IV 
RESULTS 
 
 
The results of the current study are presented in this chapter.  This chapter can be 
categorized into subject descriptive characteristics, body composition data, and 
nutritional data.  The relationships of these factors with apelin will then be presented as 
well. 
 There were 15 subjects accepted for this study; each was required to report to the 
UNCG Exercise Physiology laboratory at a consistent time across conditions in the 
morning (between 6-9 am) in a resting, post-absorptive state.  All subjects were 
apparently healthy and met the inclusion criteria.  Three subjects were eliminated from 
inclusion as they demonstrated hypoglycemia at rest and/or a hypoglycemic response to 
the 54g oral glucose load.  Therefore, the data in the results reflects the 12 subjects who 
met all of the criteria for inclusion, unless reported as (all subjects). Each subject 
successfully completed all treatment conditions, including achieving a true VO2max 
(51.15 ±11.07 mL/kg/min) during a GXT, in accordance with established criteria 
(Midgley, McNaughton, Polman, &Marchang, 2007).   
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Subject Descriptive Characteristics 
 
 
Table 14.  Subject Descriptive Characteristics. Expressed in overall terms 
and by gender.  Values shown are means ±standard deviation. *Significantly 
different between genders (p<0.05). 
 
Subject Descriptive Characteristics  
 
Variable Overall Males (n=7) Females (n=5)
Age (yrs.) 22.75 ± 2.96 22.43 ± 2.88 23.2 ± 3.35 
Weight (kg) 68.56 ± 13.08 72.14 ± 15.11 63.54 ± 8.59 
Height (cm) 171.04 ± 7.53 174.29 ± 5.82 166.5 ± 7.8 
%BF 15.32±8.09 11.02±6.11 21.33±6.84 
BMI 23.37±3.55 23.66±3.96 22.96±3.27 
SAD (cm) 17.04±6.36 19.69±3.10 18.91±3.15 
WHR  0.96±0.27 0.82±0.06 0.76±0.05 
RHR (bpm) 65 ± 9.17 63.43 ± 9.07 67.2 ± 9.86 
Resting SBP (mmHg) 119.67 ± 9.34 120.29 ± 9.83 118.8 ± 9.65 
Resting DBP (mmHg) 77.83 ± 7.29 76.57 ± 8.04 79.6 ± 6.54 
Resting MAP (mmHg) 91.78 ± 7.29 91.14 ± 8.51 92.67 ± 6.02 
VO2max (L/min) 3.49 ± 0.95 4.02 ± 0.86* 2.77 ± 0.47* 
VO2max (ml/kg/min) 51.14 ± 11.07 56.17 ± 10.32 44.09 ± 8.42 
Apelin (ng/mL) 0.511 ± 0.333 0.464 ± 0.382 0.576 ± 0.239 
 
  
Body Composition Factors 
 
% BF was evaluated using both Siri &Brozek percent body fat calculations.  In 
the graphs below, the red marker indicates a subject considered overweight but not obese 
in terms of % BF (Siri=23.36 %BF, Brozek=22.82 %BF), however, is considered 
overweight in terms of BMI (31.9 kg/m2).  The yellow marker indicates a subject that 
was considered obese using Siri % BF calculations (32.33 % BF), but overweight when 
using the Brozek equation (31.11 % BF); this subject however, was not considered obese 
in terms of BMI (27.8 kg/m2). 
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Figure 1a. Apelin vs. Siri %BF (15 
subjects).  The first figure (1a.)presents 
all 15 subjects’ data (R2=0.217, 
P=0.080), a non-significant relationship, 
however may be approaching 
significance. 
Figure 1b. Apelin vs. Siri %BF (12 
subjects). The second figure (1b.) 
presents the 12 included subjects 
(R2=0.399, P=0.028*), this relationship 
is significant at p<0.05 level.  
 
 
 The graphs above present the relationships between the subjects’ plasma apelin 
concentrations at rest and their %BF calculated using the Siri equation.  Figure 1a. shows 
the 12 included subjects and 1b. provides the reported data for all 15 subjects.  Figure 1a 
indicates a significant correlation between apelin and Siri %BF (P=0.028), while the 
relationship is non-significant in figure 1b, however it does approach significance 
(P=0.080). 
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Figure 2a.  Apelin vs. Brozek %BF (15 
subjects).   %BF was calculated using 
the Brozek equation for all 15 subjects 
(R2=0.230, P=0.070), the relationship is 
non-significant, however does approach 
significance. 
Figure 2b. Apelin vs. Brozek %BF (12 
subjects).  This figure presents the data 
for the 12 included subjects (R2=0.412, 
P=0.024*), which is significant at the 
p<0.05 level.  
 
 
The graphs above present the subjects’ baseline plasma apelin concentration by 
their %BF Brozek formula.   Figure 2a. presents the 12 included subjects and indicates a 
significant positive relationship between plasma apelin concentration and Brozek %BF 
(P=0.024), whereas figure 2b. presents all 15 subjects’ data and was non-significant 
(P=0.070), however did approach significance (p<0.05). 
The calculated values between Siri and Brozek %BF were similar, thus producing 
similar R2 values and graphical representations.  In the graph below, Siri and Brozek 
calculations are both presented on the same graph to display the similarities between the 
calculations.   
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Figure 3. Apelin vs. Siri & Brozek %BF (12 subjects).  This figure presents %BF 
calculated using both equations for the 12 included subjects.   
 
 
This chart presents baseline plasma apelin concentrations versus both Siri and 
Brozek calculated % body fat for all 12 subjects.  It is clear that the values do not deviate 
significantly from one another.  The R2-value for Siri % body fat is 0.399 (p=0.028) and 
the R2-value for Brozek % body fat is 0.412 (p=0.024).  Both of these indicate significant 
positive correlations between baseline plasma apelin concentrations and % BF of the 
subjects at the p<0.5 significant level.  
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Figure 4.  Apelin vs. Lean Mass (kg) (15 subjects). The relationship was non-significant 
(R2=0.181, P=0.114). 
 
 
This figure presents the subjects calculated lean body mass (kg) versus their 
resting plasma apelin concentration (ng/mL).  It appeared that body composition (BMI/% 
BF) had stronger correlations with apelin than body fat distribution.  In order to look at 
fat mass versus lean mass, the subjects’ lean body mass was calculated using their 
average % BF calculation.  No significant relationship was found (R2=0.181, P=0.114). 
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Figure 5a.  Apelin vs. BMI (15 subjects).  
Figure 5a presents apelin versus their 
BMI (R2=0.373, P=0.016*) indicating a 
significant positive correlation at the 
p<0.05 significance level.  
 
Figure 5b. Apelin vs. BMI (12 subjects). 
This figure presents the 12 reported 
subjects apelin vs. BMI relationship, 
which is also significant at p<0.05 level 
(R2=0.412, P=0.022*). 
 
 
In addition to %BF, BMI was calculated.  Figure 4a presents the 12 included 
subjects and indicates a significant positive relationship between plasma apelin 
concentration and BMI (kg/m2) (P=0.022).  In addition, figure 2b presents a similar 
correlation, in which all 15 subjects data was included in analysis, also indicating a 
significant positive linear correlation (P=0.016). 
Together these graphs and tables indicate that there is a positive linear 
relationship between plasma apelin concentration and % BF.  Using BMI and % BF as 
indices, both showed significant positive linear relationships at the p<0.05 significance 
level.  Using this data, the hypothesis stating that a positive linear relationship will occur 
between plasma apelin concentration and % BF can be accepted. 
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Table 15. Pearson Correlations of Anthropometric Measures. This table displays the 
correlations between anthropometric measurements and baseline plasma apelin 
concentrations. Siri %BF (0.028) and Brozek %BF (0.024), BMI (0.022) and SAD 
(0.029) were all found to be significant via Pearson’s 2-tailed analysis (p<0.05).  
*Correlation is significant at the 0.05 level (2-tailed) 
 
Pearson Correlations of Anthropometric Measures 
 
 Pearson Correlation Significance 
Siri %BF 0.631* 0.028 
Brozek %BF 0.642* 0.024 
BMI 0.649* 0.022 
Sagittal (cm) 0.628* 0.029 
WHR 0.178 0.579 
WC (cm) 0.555 0.061 
 
 
Body Fat Distribution Factors 
 
In the graphs below, the red marker indicates a subject considered overweight but 
not obese in terms of %bf (Siri=23.36 %BF, Brozek=22.82 %BF), however, is considered 
overweight in terms of BMI (31.9 kg/m2).  The yellow marker indicates a subject that 
was considered obese using Siri %BF calculations (32.33 %BF), but overweight when 
using the Brozek equation (31.11 %BF); this subject however, was no considered obese 
in terms of BMI (27.8 kg/m2). 
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Figure 6a. Apelin vs. SAD (cm) (15 
subjects).Figure 6a.presents SAD vs. 
apelin for all 15 subjects (R2=0.347, 
P=0.021*) indicating a significant 
positive relationship at the p<0.05 
significance level. 
 Figure 6b. Apelin vs. SAD (cm) (12 
subjects).  This shows the 12 included 
subjects’ baseline plasma apelin 
concentration vs. SAD (R2=0.394, 
P=0.029*) indicating a significant 
positive correlation at p<0.05 level.  
 
 
The figures above present SAD versus baseline plasma apelin concentration.  
Figure 5a presents the data for the included 12 subjects and indicates a significant 
positive linear relationship between SAD and plasma apelin (P=0.029).  Similarly, figure 
5b. presents SAD versus plasma apelin for all 15 subjects and indicates a significant 
positive linear correlation (P=0.021).  
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Figure 7a. Apelin vs. WHR (15 
subjects). Figure 7a presents WHR 
versus apelin for all 15 subjects 
(R2=0.034, P=0.511) this relationship is 
non-significant at p<0.05 level. 
 
Figure 7b. Apelin vs. WHR (12 
subjects).  Figure 7b. presents the 12 
included subjects’  apelin concentration 
vs. WHR; the relationship is non-
significant at the p<0.05 significance 
level (R2=0.032, p=0.579).  
 
 
 
 
Figure 8a. Apelin vs. WC (cm) (15 
subjects). It is non-significant 
(R2=0.264, P=0.050), however does 
approach significance. 
Figure 8b. Apelin vs. WC (cm) (12 
subjects).  Presents the 12 included 
subjects, the relationship was non-
significant (R2=0.308, p=0.061), 
approaches significance at p<0.05 level
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No significant relationship was found between WHR and apelin in either group.  
The WC measurements of the 12 subjects studied has a small range and indicated a 
positive linear relationship approaching significance (R=0.555, p=0.061) at the p<0.05 
significance level.  However, when all 15 subjects were included, the relationship was 
significant (P=0.050). 
Participant Food Consumption 
 
 
Table 16. Mean Values for Nutritional Data.  This table presents the average daily 
nutritional data for the subjects collapsed across all 3 time points, providing the mean and 
standard deviation.  The data is also divided into male and female subjects. 
 
Mean Values for Nutritional Data 
 
 Group Mean ± SD Males (n=7) Females (n=5) 
Total kCal 2161.54±544 2446.18±989.10 1763.06±518.92
CHO (g) 262.18±111.61 302.51±126.18 205.72±59.54 
CHO (kCal) 1048.72±446.46 1210.04±504.72 822.87±238.15 
Protein (g) 99.25±40.42 111.97±46.37 81.43±24.21 
Protein (kCal) 396.99±161.66 447.89±185.48 325.72±96.84 
Total Fat (g) 81.62±40.14 89.28±46.34 70.88±31.04 
Total Fat (kCal) 734.59±361.26 803.56±417.02 637.96±279.34 
Vitamin A (mcg) 473.86±264.15 548.86±316.42 368.85±134.45 
Vitamin C (mg) 98.41±101.03 122.65±130.59 64.48±4.17 
Vitamin E (mg) 13.25±3.49 13.32±2.90 13.16±0.85 
Zinc (mg) 9.40±0.68 9.57±0.53 9.17±0.85 
 
. 
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Macronutrients 
 
 
Table 17. Average Daily Macronutrient Intake vs. Recommended.  This table presents the 
subjects’ actual average macronutrient intake in terms of % of total kCal intake and also 
presents the recommended average macronutrient intake as a percentage of total kCal 
consumption. 
 
Average Daily Macronutrient Intake vs. Recommended 
 
Macronutrient % Range (Actual) % Range 
(Recommended) 
Fat 26-44% 20-35% 
Protein 11-28% 10-35% 
Carbohydrates 42-57% 45-65% 
 
 
Table 18. Percent Macronutrient Intakes of Total kCal.  The reported percentage of total 
calories consumed for each macronutrient pooled across visits. 
 
Percent Macronutrient Intakes of Total kCal 
 
Subject 
 
Gender %CHO %Protein %Fat 
1 Male 57.65% 21.26% 26.06% 
2 Female 49.25% 17.22% 35.42% 
3 Female 47.27% 16.67% 37.85% 
4 Female 41.89% 20.99% 44.63% 
6 Male 46.11% 26.62% 27.67% 
7 Male 50.48% 11.22% 37.77% 
8 Male 52.13% 18.53% 28.92% 
11 Male 35.95% 27.88% 35.50% 
12 Female 52.67% 16.06% 29.83% 
13 Male 53.09% 14.19% 27.94% 
14 Female 43.24% 22.09% 28.02% 
15 Male 47.31% 16.62% 40.86% 
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Figure 9. Apelin vs. Total kCal Intake.  This figure presents the 12 reported subjects total 
reported kCal intake versus plasma apelin concentration (R2=0.073, P=0.395) indicating 
no significant relationship. 
 
 
 
 
Figure 10. Apelin vs. % Dietary CHO. This figure presents the 12 reported subjects’ 
reported %CHO intake by plasma apelin concentration (R2=0.010, P=0.755), no 
significant relationship was found. 
 
0
500
1000
1500
2000
2500
3000
3500
4000
0.0000 0.2000 0.4000 0.6000 0.8000 1.0000 1.2000
T
ot
al
	k
Ca
l
Apelin	(ng/mL)
Apelin	vs.	Total	kCal	Intake	
(12	subjects)
r=0.271
35
40
45
50
55
60
0.0000 0.2000 0.4000 0.6000 0.8000 1.0000 1.2000
%
CH
O
Apelin	(ng/mL)
Apelin	vs.	%	Dietary	CHO
(12	subjects)
r=0.101
57	
 
 
Figure 11. Apelin vs. % Dietary Protein. This figure presents the subjects reported protein 
intake as a percentage of their total kcal intake versus plasma apelin (R2=0.169, 
P=0.185).  A slightly negative linear relationship is seen, however not significant. 
 
 
 
 
Figure 12. Apelin vs. % Dietary Fat.  The figure above presents the subjects’ reported fat 
intake as a percentage of their total kcal intake versus plasma apelin concentration 
(R2=0.132, P=0.247).  A slightly positive linear relationship can be seen, however is not 
significant. 
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Table 19. Mauchly’s Test of Sphericity for Dietary Factors.  The data indicates that 
sphericity was found for all nutritional variables analyzed. 
 
Mauchly’s Test of Sphericity for Dietary Factors 
 
Source Mauchly’s W Approx. Chi-
Square 
df Sig. Greenhouse-
Geisser 
Total kCal 0.926 0.767 2 0.681 0.931 
CHO 0.926 0.770 2 0.680 0.931 
Protein 0.937 0.649 2 0.723 0.941 
Total Fat 0.952 0.496 2 0.780 0.954 
Vitamin A 0.495 7.037 2 0.030* 0.664 
Vitamin C 0.627 4.669 2 0.097 0.728 
Vitamin E 0.601 5.100 2 0.078 0.715 
Zinc 0.697 3.607 2 0.165 0.768 
 
 
The data provided in the table presented above suggests that there is sphericity 
found with each variable except for Vitamin A, indicating a normal distribution.  Because 
sphericity was found with each variable, a test of within-subjects effects was performed 
to determine if there were any significant relationships, and none were found. Mauchly’s 
test of sphericity did not show normal distribution for Vitamin A, therefore a Spearman’s 
correlational analysis was done.  No significance was found with Spearman’s 
correlational analysis.  
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Table 20. Tests of Within-Subjects Effects of Dietary Factors. Since sphericity was 
assumed for all variables using Mauchly’s Test of Sphericity, a test of within-subjects 
effects was done for each variable. No significance was found. 
 
 
 
The data above suggest that assuming normal distribution for each factor besides 
vitamin A, there were no significant differences between the average daily nutritional 
intakes of each subject between the three time points.   Because the subjects did not have 
significantly different dietary intakes at each visit, the dietary data was collapsed across 
time points, providing an average intake for each variable across all time points.  
  
Tests of Within-Subjects Effects of Dietary Factors 
 
Source Type III Sum of 
Squares 
df Mean Squares F Sig. 
Total kCal 100705.92 2 50352.9 .402 0.674
Error (kCal) 2754193.15 22 125190.6   
CHO 7825.33 2 3912.66 1.221 0.314
Error (CHO) 70505.30 22 3204.8   
Protein 933.64 2 466.8 1.601 0.224
Error 
(Protein) 
6413.96 22 291.5   
Fat 159.95 2 80 0.351 0.708
Error (Fat) 5005.8 22 227.5   
Vitamin A 571483693392 2 285741846696 0.601 0.557
Error (Vit A) 10458702789500 22 475441035886   
Vitamin C 2562.53 2 1281.26 0.217 0.807
Error (Vit C) 129874.6 22 5903.39   
Vitamin E 387.95 2 193.98 1.291 0.295
Error (Vit E) 3306.26 22 150.29   
Zinc 9.28 2 4.64 0.297 0.746
Error (Zinc) 343.12 22 15.6   
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Antioxidants 
 This section presents the subjects’ antioxidant and micronutrient intake in relation 
to baseline plasma apelin levels.  Each micronutrient (Vitamin A, C, and E) were 
analyzed individually then pooled to create an average daily total micronutrient 
antioxidant intake and their average % of RDA consumed daily.  The outliers are 
highlighted in red.  
 
 
 
Figure 13. Apelin vs. Vitamin A (mcg). This graph presents the subjects’ baseline plasma 
apelin concentration in relation to their average daily Vitamin A intake (mg).  The data 
indicates that the relationship is not significant (R2=0.030, =0.592). The red marker is an 
outlier for normal vitamin A intake.  
 
 
0
200
400
600
800
1000
1200
1400
0 0.2 0.4 0.6 0.8 1 1.2
V
it
am
in
	A
	(
m
cg
)
Apelin	(ng/mL)
Apelin	vs.	Vitamin	A	(mcg)
(12	subjects)
R=0.172
61	
 
 
Figure 14. Apelin vs. Vitamin C (mg). This graph presents the subjects’ baseline plasma 
apelin concentration in relation of average daily Vitamin C intake (mg).  This relationship 
is weak and not significant (R2=0.048, P=0.496). The red marker is an outlier for normal 
vitamin C intake.  
 
 
 
 
Figure 15. Apelin vs. Vitamin E (mg). This graph shows the baseline plasma apelin 
concentration versus the subjects’ average daily Vitamin E intake. The data indicates a 
significant positive linear realtionship between vitamin E intake and plasma apelin 
(R2=0.433, P=0.020*) 
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Figure 16. Apelin vs. % of RDA TAC.   
 
 
This figure presents the subjects’ baseline plasma apelin level by % of total 
antioxidant consumption (TAC).  The % RDA consumed was calculated by summing the 
vitamin percentage of A, C, and E consumed compared to the RDA.   The data indicates a 
weak negative linear correlation that is not significant (R2=0.038, P=0.544). The red 
marker is an outlier for normal vitamin total intake.  
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Figure 17.  Apelin vs. % RDA TAC (adjusted). This graph presents the same data as 
above without the outlier.  There was one participant who reported consuming >200% of 
the RDA for total antioxidant content.  When removed the range of data is significantly 
smaller, however there was still no significant effect (R2=0.075, P=0.415). 
 
 
Table 21. Pearson Correlations of Micronutrient Factors.This table presents the pearson 
correlations of each micronutrient variable in terms of apelin.   
 
Pearson Correlations of Micronutrient Factors 
 
 R-value R2-value Significance 
Vitamin A (mcg) 0.172 0.030 0.592 
Vitamin C (mg) 0.218 0.048 0.496 
Vitamin E (mg) 0.658 0.433 0.020* 
Zinc (mg) 0.024 0.001 0.940 
% RDA 0.195 0.038 0.544 
% RDA 
(adjusted) 
0.274 0.075 0.415 
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Zinc 
 
 
 
 
Figure 18. Apelin vs. Zinc (mg).  This graph presents the baseline plasma apelin 
concentration (ng/mL) versus average daily Zinc intake (mg).  No significance was found 
(R2=0.001, P=0.940). 
 
 
It was hypothesized that higher zinc intake would illicit lower plasma apelin 
levels at baseline, however the data shows that there was no significant relationship 
between zinc intake and baseline plasma apelin concentrations in the studied cohort. 
Therefore, we cannot accept or reject the hypothesis stating that increased zinc intake 
would decrease plasma apelin concentrations in healthy, young adult subjects.  Further 
research should be done using larger cohort and possibly using diet intervention. 
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Apelin 
 
 
Table 22. Resting Plasma Apelin Concentrations.  This table presents the resting, fasted 
plasma apelin concentrations of each subject at each visit. 
 
Resting Plasma Apelin Concentrations 
 
Subject Visit 1 Visit 2 Visit 3 
1 0.393 0.270 0.424 
2 0.627 0.578 0.503 
3 0.784 0.575 0.832 
4 0.564 1.186 0.641 
5 0.268 0.2235 0.290 
6 0.649 1.228 1.377 
7 0.907 0.714 0.945 
8 0.505 0.2435 0.2180 
9 0.701 0.332 0.193 
10 0.112 0.364 0.246 
11 0.582 0.304 0.237 
12 0.112 0.109 0.1535 
 
 
 
 
 Figure 19.  Apelin vs. VO2max (mL/kg/min).  This figure presents the 15 
subjects’ baseline plasma apelin by maximal oxygen consumption. Is it fitness or fatness? 
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This figure presents the subjects’ VO2max versus baseline plasma apelin 
concentration (R2=0.186, P=0.186) indicating a weak negative relationship.   
 
 
 
Figure 20. Apelin vs. Harris-Benedict Equation. Non-significant (R2=0.044, P=0.454). 
 
 
 In order to determine the caloric balance of the subjects studied, the subjects’ 
basal metabolic rate was calculated and adjusted for physical activity, then analyzed in 
relation to their plasma apelin concentration fasting and at rest.  
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CHAPTER V 
DISCUSSION  
 
 
This chapter provides insight into the results of the presented study as well as 
compares the results to the literature, as well as suggests future directions.  The primary 
purposes of this study were to evaluate whether diet and/or body composition influence 
resting plasma apelin concentration.  An additional aim was to establish a baseline resting 
plasma apelin concentration for healthy young adults, as much of the research on apelin 
has been focused on clinical populations.  It is important to establish a proper baseline 
plasma apelin concentration for healthy populations, as it is difficult to analyze outcomes 
of exercise and interventional studies without an appropriate baseline against which to 
compare apelin concentration.  Subjects were recruited on a volunteer basis, the majority 
being undergraduate students in the Kinesiology department at UNC-Greensboro.  This 
may explain the skewed VO2max scores in which all subjects were above average, with 
most subjects in the excellent to superior range for their age and gender.  This indicates 
our subject group was more fit than the average person in their age group and gender.   In 
order to analyze this we looked at the subjects VO2max scores versus their plasma apelin 
concentration and no significant relationship was found. 
 The subjects had normal weight and height for this age group (22.75±2.96 years).  
The average %BF (15.32±8.09%; M=11.02±6.11, F=21.33±6.84%) and BMI 
(23.37±3.55 kg/m2) of the subjects was normal respective to their gender (based on CDC 
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norms). One female subject was considered overweight via BMI and obese in terms of 
%BF.  In addition, one male subject was considered obese I via BMI, however was 
considered only overweight in terms of %BF.  
The subjects had a normal resting heart rate (65±9.17 bpm) and normal systolic 
and diastolic blood pressures (119.67±9.34 mmHg SBP; 77.83±7.29 mmHg DBP).  The 
maximal oxygen consumption (51.14±11.07 ml/kg/min) is considered superior for their 
age group; each subject was in the excellent to superior range based on ACSM values 
(Ehrman, 2010). 
Body Composition   
The first proposed hypothesis predicted that a positive relationship would exist 
between percent body fat and plasma apelin concentration at rest.  To evaluate the 
subjects’ % BF, 7-site skinfold analysis was performed upon the first visit.  Both Siri and 
Brozek %BF calculations were used and not found to be significantly different from one 
another.  Both Siri %BF (P=0.028) and Brozek (P=0.024) calculations showed a 
significant positive linear correlation with baseline plasma apelin concentration at p<0.05 
significance level.  While DEXA is the gold standard and should be looked at in the 
future, we were limited to the skinfold analysis method to establish % BF in individuals.  
BMI, which is a preferable index for populations, was also examined.   
BMI is a widely used and accepted form of classifying subjects as overweight and 
obese, however it is generally use as a population index.  BMI is used more clinically to 
categorize populations. Similar to Siri and Brozek %BF, the data on BMI compared to 
resting apelin also revealed a significant positive linear relationship (r=0.649, P=0.022) at 
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p<0.05 significance level.  Surprisingly, this relationship is slightly stronger than both 
Siri and Brozek %BF, indicating that all three measurements may be used as a predictor 
of resting plasma apelin concentrations. This data is supported by previous literature in 
which, other studies found that as %BF and BMI increased, so did apelin, indicating there 
is a positive relationship between these factors and resting apelin concentrations. (H. J. 
Ba et al., 2014; Daviaud et al., 2006; Heinonen et al., 2009; Sheibani et al., 2012). . 
While BMI is typically used as an index for population based studies, and % BF is 
typically considered more accurate for individual.  The data in this study indicated that 
BMI and %BF are both good indicators for predicting resting plasma apelin levels, with 
BMI having a slightly stronger relationship with apelin than %BF. 
Body Fat Distribution  
In addition to 7-site skinfold measurements and BMI several other measurements 
were taken prior to the first treatment condition on their first visit to the lab.  SAD and 
WHR were measured to establish the subjects’ body fat distribution.  
The data collected shows a significant positive linear correlation between plasma 
apelin concentration at rest and SAD (cm) (r=0.628, P=0.029) at the p<0.05 significance 
level.  To further support this finding, the strength of the correlation increases when SAD 
is analyzed for all 15 subjects (r=0.589, P=0.021).   To our knowledge this is the first 
study which reports a significant relationship between apelin and visceral obesity (SAD 
and WC).  This is important because while several studies have reported significant 
relationships between BMI and %BF and apelin, this study indicates that the location of 
body fat in addition to proportion of body fat may influence apelin concentration.  
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SAD is a direct measurement of visceral adiposity.   A second measure of visceral 
adiposity, WC, was analyzed.  In addition, WHR was established for each participant, 
which is an indicator of increased cardiometabolic risk in relation to visceral obesity.  
SAD has been suggested to be a stronger indicator of body fat distribution for visceral 
obesity than WHR (Ohrvall, Berglund, & Vessby, 2000; U. Risérus et al., 2010a; Ulf 
Risérus et al., 2004)which is controversial.  It has been suggested that gender and amount 
of obesity may be a factor towards increased cardiometabolic risk due to visceral 
obesity(U. Risérus et al., 2010a).  
Several studies have examined SAD in terms of assessing metabolic risk.  SAD 
has been proved an accurate indicator of visceral fat area on the L4-L5 level when 
compared to multiple scans compared to MRI (Kvist, 1988; U. Risérus et al., 2010a).  
Several studies have shown SAD to be a better indicator of CVD risk and strongly 
associated with glucose intolerance, mortality, cholesterol, HTN, and general risk for 
metabolic disorders independent of BMI (Kvist, 1988; Ohrvall et al., 2000; U. Risérus et 
al., 2010a; U. Risérus, De Faire, Berglund, & Hellénius, 2010b; van der Kooy, Leenen, 
Seidell, Deurenberg, & Visser, 1993).  However, contradictory evidence has been 
published indicating that SAD is only comparable to WC and WHR as an indicator of 
visceral fat in obese men, whereas WC and WHR are reported to be superior to SAD 
when assessing visceral fat in women (Kvist, 1988; van der Kooy et al., 1993) 
While not an ideal measure, WHR was also analyzed; the reported results indicate 
that the relationship is not significant (r=0.184, P=0.579) at the p<0.05 significance level. 
A better measure of visceral adiposity, WC is a commonly used indicator of body fat 
71	
distribution, and in conjunction with BMI, WC may predict increased risk for metabolic 
dysfunction in normal and overweight populations (National Heart Lung and Blood 
Institute & National Institutes of Health (NIH) National Heart, Lung, and Blood Institute, 
1998).  The data collected shows a positive linear correlation between WC, however not 
significant (p<0.05), it is approaching significance (r=0.555, P=0.061).  These results 
suggest that WC may be a good correlate to support the hypotheses regarding body fat 
distribution.  Interestingly, when all 15 subjects are included, the relationship between 
plasma apelin concentration and WC becomes significant (r=0.514, P=0.050). 
The data collected regarding body fat distribution suggests that as visceral 
adiposity increases, so does plasma apelin concentration at rest.  While, only SAD had a 
significant positive linear relationship with plasma apelin concentrations at rest (r=0.628, 
P=0.029*), the relationship between WC and apelin concentrations at rest approached 
significance (r=0.555, P=0.061) at the p<0.05 significance level.   Interestingly, when all 
15 subjects were included in analysis, the relationship between WC and plasma apelin 
becomes significant (r=0.514, P=0.050) and SAD had an even stronger relationship than 
the 12-subject correlation (r=0.589, P=0.021).   In contrast, the relationship between 
WHR and plasma apelin concentrations at rest was non-significant (r=0.178, P=0.579), 
and was still non-significant when all 15 subjects were included.  
According to the data collected, the hypothesis stating that subjects exhibiting 
increased visceral obesity would have increased baseline plasma apelin concentrations 
can be accepted.  While the strength of the relationships varied dependent on the measure 
analyzed, all three indicated a positive linear correlation between visceral obesity and 
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plasma apelin concentrations at rest.  Several studies have proven associations between 
plasma apelin concentrations and BMI, however few of these studies reported WC, 
WHR, or SAD to predict visceral adiposity.  Unfortunately these studies only reported 
WC (cm) in the descriptive characteristics tables and did not report relationships between 
WC and plasma apelin concentrations (Heinonen et al., 2009; Soriguer et al., 2009). 
Macronutrient Consumption 
In terms of macronutrients, our subjects reported diets similar to those reported by 
the USDA NHANES study from 2011-2012 in “What We Eat in America.”  On average, 
the subjects reported consuming about 2,049 total kCal per day, which is in line with the 
reported 2191 kCals per day consumed by the average American as reported by 
NHANES, 2011 as well as the 2,000-3,000 kCal diet recommended by the 
USDA/USHHS.  In general, the participants were active and healthy, eating well-rounded 
diets with an in-depth education about nutrition, according to their PAR-Q and pre-
participation questionnaires.   
The third hypothesis stated that individuals consuming a high fat diet would have 
increased plasma apelin concentration at rest.  Only 3 subjects had diets with considered 
high in fat (>35% of total kCal) and had varied confounding factors that may have 
influenced the diet relationship with plasma apelin.  Two of the subjects were considered 
highly active, where as the one sedentary subjects had higher plasma apelin levels when 
compared to the two active subjects.   The relationship of high fat diets and apelin could 
not be analyzed with only three subjects as there are not enough subjects to power the 
analysis.  It was important to look at macronutrient intake because animal studies have 
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shown that a HFD will induce maximal insulin resistance associated with increased 
ectopic fat and oxidative stress (Mei et al., 2014).  Humans consuming diets high in fat 
(>35% of total kCal intake), generally report increased saturated fat intakes, and are at 
risk for health benefits due to overconsumption of calories (Ehrman, 2010).  No 
significant relationships were found between apelin and the reported total kcal intake or 
macronutrient percentages of total kcal intake (%CHO, %Protein, % Fat).    
Antioxidant Consumption 
The subjects’ dietary intake was analyzed via 3-day food logs and their 
micronutrient consumption was evaluated using the USDA food nutrient database.  This 
provided the subjects’ Vitamin A, C and E intake based on the reported food 
consumption.  The USDA Nutrient Data Laboratory reported vitamin A in retinol activity 
equivalents (RAE - mcg) and vitamins C, E and zinc in milligrams (mg). It was 
hypothesized that individuals with low antioxidant consumption will have increased 
plasma apelin concentrations.  However, no subjects reported consuming low levels of 
antioxidants in their diets. 
Vitamins A, C, and E were analyzed individually, and then pooled to explore 
possible relationships between these micronutrients and plasma apelin concentration at 
rest.  It appears that vitamins A, C, and E may influence plasma apelin concentrations in 
different ways.  Vitamins A and C intake indicate a slight negative correlation, however 
this relationship is weak (Vitamin A: P=0.592; Vitamin C: P=0.496).  Conversely, 
Vitamin E suggests a significant positive correlation (r=0.658, P=0.020) One subject 
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reported consuming >200% of the recommended daily intake of the antioxidants, this 
subject may have skewed the results. 
In order to calculate total antioxidant consumption the vitamin percentage of 
summed vitamins A, C, and E compared to the RDA, giving a total percentage of 
recommended antioxidants consumed.  Once pooled, the percentage of RDA consumed 
and plasma apelin did not have a significant relationship, but (r=0.195, P=0.544).  
From this data, the hypothesis stating that increased antioxidant intake would be 
correlated with lower plasma apelin concentrations cannot be supported or fully rejected.  
There were not enough individuals outside of the RDA range to analyze high versus low 
consumption.  
Zinc Consumption 
 In addition to vitamins A, C, and E, reported zinc consumption was also analyzed 
using the USDA nutrient database to establish an average daily consumption for each 
subject.  It was proposed that those subjects consuming a higher zinc intake would have 
decreased apelin concentrations at rest.  This hypothesis cannot be accepted.  The data 
collected suggests that there is no significant relationship between average daily zinc 
consumption (mg) and plasma apelin concentrations at rest.    
Apelin 
As shown (see table 13), there have been wide ranges of plasma apelin 
concentrations reported by various research groups.  Our values of 0.511±0.333 are close 
to the average (0.635 ng/mL) of the previously reported apelin concentrations in healthy 
human controls.  At first it was thought that the difference in reported apelin 
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concentrations was due to the year the values were reported in which studies by 
Papadopoulos (2013), Mesmin (2010), and Castan-Laurell (2008) all seemed similar.  In 
addition, it seemed that several of the more recent studies have reported significantly 
higher apelin scores including Alexiadou (2012) and Kadoglou (2012), using kits 
purchased from the same company, but shipped from a different location (Belmont, CA 
and Strausburg, France) suggesting there may have been a difference in assay kits used 
between research groups.  Therefore comparisons are difficult within the literature, even 
when using similar Phoenix Pharmaceutical apelin-12 kits, as the facility it originates 
from seems to be a factor. 
Future Directions 
It is suggested that future studies should include a larger cohort of subjects with a 
wider range of diets as well as a larger range for each of the reported variables.  To 
further look at diet, future studies should control for diet in interventional as well as 
observational studies.  It is not suggested that the high antioxidant intakes should be 
looked at further as there have been studies reporting negative side effects to high 
antioxidant supplementation.  It was difficult to analyze antioxidant intake versus apelin 
concentration as we only had 1 subject who exhibited high antioxidant intake (>200% 
RDA) and we had no subjects reporting extremely low antioxidant intake.  Future studies 
should include larger cohorts including a wider range for BMI due to inconsistency 
between studies, where several found no relationship between BMI and apelin(Chong, 
Gardner, Morton, Ashley, & McDonagh, 2006; Erdem, Dogru, Tasci, Sonmez, & Tapan, 
2008; Soriguer et al., 2009; Tasci et al., 2007).  In terms of body fat distribution, more 
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sophisticated forms of measurement should be used such as MRI and/or DEXA would be 
useful tools to analyze the role of body fat distribution on plasma apelin concentrations.  
It is suggested that this study should be done with a larger cohort and with 
subjects of a wider range of calorie and nutrient intakes to determine if the addition of a 
high fat diet would influence resting plasma apelin concentration.  It will also be 
important to indicate the source of fats and type of fats (MUFA, PUFA, SFA) in future 
studies as it is suggested that the types of fat consumed have more of an effect on 
increased metabolic disturbances than total fat intake (Alhazmi et al., 2012; Peairs et al., 
2011). Studies have shown that postprandial oxidative stress, particularly in AT is 
influenced by the various types of fats ingested (Meza-Miranda et al., 2014).  Therefore, 
not only is the overall amount of fat consumed a concern, but the type of fats consumed 
may also influence oxidative stress.   It is important to note that there are variations in the 
different types of fat consumed such as saturated fatty acids (SFAs), polyunsaturated 
fatty acids (PUFAs) and its subtypes, and monounsaturated fatty acids (MUFAs).   
Studies have investigated the protective effects of MUFAs and PUFAs versus SFAs in 
terms of oxidative stress and IR, but it remains unclear as to how ingestion of these fats 
may influence apelin levels at rest or in response to exercise/glucose stimuli.   
Conclusion 
In conclusion, this study includes a small cohort of subjects all had stable resting 
plasma apelin levels across visits and it does not appear that their dietary factors 
influenced their apelin levels.  In contrast, %BF, BMI and SAD suggest that these factors 
77	
are significantly related to resting plasma apelin whereas WC approached significance.  
Dietary intakes showed no significant effect on apelin.
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APPENDIX A 
 
HEALTH HISTORY, DRUG USAGE, AND  
FITNESS ACTIVITY QUETIONNAIRE 
 
 
Subject:        
ID:          
      
Health History 
Blood Pressure:  SBP/DBP: ___________________ 
Do you have any musculoskeletal illnesses or injuries that would restrict your 
participation in either a maximal or submaximal exercise bout (as performed on a 
treadmill or with use of free weights while performing a squatting motion)?   
    
        YES                               NO                            
If yes, please describe.         
               
 
Have you ever been diagnosed with cardiovascular disorders (heart problems, high blood 
pressure, high cholesterol, etc.)?    YES                   NO                            
If yes, please describe.         
              
Have you ever been diagnosed with metabolic disorders (diabetes, etc.)? 
        YES                               NO                            
If yes, please describe.         
              
Could you currently be pregnant?   YES                             NO     N/A                             
 
Please list any major illnesses, hospitalizations, or surgical procedures within the last two 
years. 
              
              
 
Drug/Supplement Usage 
 
Are you a current smoker/Tobacco user?  YES                             NO 
 
Have you every smoked/tobacco use in the past?      YES                             NO    
If yes, please describe history.         
             
 
Are you currently taking any medication(s)?  YES                             NO                                
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If yes, please list name of medication(s), reason for and length of administration. 
             
 __________________________________________________________________ 
 
Are you currently taking any nutritional/vitamin supplements?   
        YES                             NO                                
 
If yes, please list name of supplement, reason for and length of administration. 
              
 
Are you taking energy bars or drinks on a routine basis? YES  NO 
 
 
Fitness Activity       
 
Please describe your current participation in the following types of exercise: 
 
1. Aerobic (aerobic classes, walking, jogging, stair climbing, hiking, cycling, running 
swimming etc.)  If more than one activity please list separately. 
 
Frequency (# of days per week):     
Duration (time spent per session):    minutes 
Intensity (difficulty level):  light    somewhat hard hard     very hard  
 
How long have you been participating in the aerobic activity described above? 
Less than three months 3-6 months 6-12 months      greater than 12 months 
 
Additional comments:           
            
 __________________________________________________________________ 
 
2. Anaerobic (weight training, sprinting, boxing, martial arts, interval training, etc.) 
 
Frequency (# of days per week):     
Duration (time spent per session):    minutes 
Intensity (difficulty level):  light    somewhat hard hard     very hard  
 
How long have you been participating in anaerobic activity as described above? 
Less than three months 3-6 months 6-12 months      greater than 12 months 
 
Additional comments:          
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3. Organized or Recreational sports (basketball, soccer, lacrosse, etc.) 
 
Type of sport(s):          
             
Frequency (# of days per week):     
Duration (time spent per session):    minutes 
Intensity (difficulty level):  light    somewhat hard hard     very hard  
 
How long have you been participating in sports activity as described above? 
Less than three months 3-6 months 6-12 months      greater than 12 months 
 
Additional comments:           
             
 
4.  Other activities 
 
Type of activities (Thai chi, yoga, stretching activities,  
Classification (to be assessed by researchers—leave blank) 
Need to confirm aerobic capacity by maximal oxygen uptake test. 
 
 
Trained  Untrained 
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APPENDIX B 
 
AHA/ACSM HEALTH/FITNESS FACILITY PRE-PARTICIPATION SCREENING 
QUESTIONNAIRE 
 
 
Assess your health status by marking all true statements 
 
History: 
 
You have had: 
 
__________________ a heart attack 
__________________ heart surgery 
__________________ cardiac catheterization coronary 
__________________ angioplasty (PTCA) 
__________________ Pacemaker/implantable cardiac defibrillator 
__________________ rhythm disturbance 
__________________ heart valve disease 
__________________ heart failure 
__________________ heart transplantation 
__________________ congenital heart disease  
 
Symptoms: 
 
_________________ You experience chest discomfort with exertion 
_________________ You experience unreasonable breathlessness 
 _________________You experience dizziness, fainting, or blackouts 
_________________ You take heart medications  
 
Other health issues: 
 
________________ You have diabetes 
________________ You have asthma or other lung disease 
________________ You have burning or cramping sensation in your lower legs when 
walking short distances 
________________ You have musculoskeletal problems that limit your physical activity 
________________ You have concerns about the safety of exercise 
________________ You take prescription medication(s) 
________________ You are pregnant  
 
If you marked any of these statements in this section, consult you physician or other 
appropriate health care provider before engaging in exercise. You may need to use a 
facility with a medically qualified staff. 
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Cardiovascular risk factor : 
 
___________________ You are a man older than 45 years 
___________________ You are a woman older than 55 years, have had a hysterectomy, 
or are postmenopausal 
___________________ You smoke, or quit smoking within the previous 6 month 
___________________ Your blood pressure is >140/90 mm Hg 
___________________ You do not know your blood pressure 
___________________ You take blood pressure medication 
___________________ Your blood cholesterol level is > 200 mg/dl 
___________________ You do not know your cholesterol level  
___________________ You have a close blood relative who had a heart attack or heart 
surgery before age 55 (father or brother) or age 65 (mother or sister)  
___________________ You are physically inactive (i.e., you get <30 minutes of physical 
activity on at least 3 per week)  
___________________ You are >20 pounds overweight  
 
If you marked two or more of the statements in this section you should consult your 
physician or other appropriate health care provider before engaging in exercise. 
You will benefit from using our facility with a professionally qualified exercise staff 
to guide your exercise program. 
 
___________________ None of the above  
 
You should be able to exercise safely without consulting your physician or other 
appropriate health care provider in a self-guided program or almost any facility 
including our facility that meets your exercise program needs. 
 
Modified from American College of Sports Medicine and American Heart Association. 
ACSM/AHA Joint Position Statement: Recommendations for cardiovascular screening, 
staffing, and emergency policies at health/fitness facilities. Medicine and Science in 
Sports and Exercise 1998: 1018  
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APPENDIX C 
	
SKINFOLD MEASUREMENT DATA FORM 
	
 
Chest ____________        _____________                  
Average___________ 
 
Triceps ____________        _____________ Average___________ 
 
Axilla  ____________ ____________                    
Average___________ 
 
Subscapular  ____________ _____________ Average___________ 
 
Abdominal  ____________ ____________ Average___________ 
 
Suprailium ____________ _____________ Average___________ 
 
Thigh ____________ ____________ Average___________ 
 
Total    7 = _______mm Total  3 = __________mm 
 
Males:   
  
Db (3) = 1.10938 - (0.0008267 x 3) + (0.0000016 x(3)2) - (0.0002574 x age) 
Db (7) = 1.112 - (0.00043499 x 7) + (0.00000055 x(7)2) -(0.00028826 x 
age) 
 
Women: 
Db (3) = 1.0994921 - (0.0009929 x 3) + (0.0000023 x(3)2) - (0.0001392 x 
age) 
Db (7) = 1.097 - (0.00046971 x 7) + (0.00000056 x(7)2) - (0.00012828 x 
age) 
% Body Fat = {(4.95/ Db) - 4.50} x 100   (Siri, 1961). 
% Body Fat = {(4.57/ Db) - 4.142} x 100 (Brozek et al., 1963). 
 
Siri (1961)  Brozek (1963) 
% Body Fat__________(3)  % Body Fat__________(3) 
% Body Fat__________(7)  % Body Fat__________(7) 
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APPENDIX D 
 
VO2MAX TEST DATA FORM 
 
 
Date:      
Subject:     
ID:      
Gender:          
Age:      
Height:     
Weight:     
Resting HR:     
Resting BP:     
Relative Humidity:    
Waist to Hip Ratio ______________ 
Atmospheric Pressure: _____  
Sagittal girth       ________________ 
Room Temperature:    
 
Time 
(min) 
Workload 
speed/grade 
HR 
(bp
m) 
RPE VO2 
(ml/kg/
min) 
VCO2 
(ml/kg/mi
n) 
R VE 
(L/mi
n)  
Comments 
1         
2         
3         
4         
5         
6         
7         
8         
9         
10         
11         
12         
13         
14         
15         
 
Blood taken     pre ______ post _____ 1hr post ____ 24hr _____ 
Glucose concentration  pre  ______ post _____ 1hr post ____ 24hr _____ 
Hct   pre  ______ post _____ 1hr post ____ 24hr _____   
Diet papers brought in and discussed ________ Returned a copy  ____ 
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APPENDIX E 
 
FOOD DIARY DATA FORM 
 
 
Please list ALL food and drink consumed during the three days before each 
experimental day. Use a separate sheet for each day and refer to the following examples 
for ideas on how specific you should be. Please include all added antioxidants (Vit C, E, 
A, etc.). 
7:00 a.m. Eggs (fried) 
 
wheat bread 
jelly (grape) 
orange juice (conc.) 
2 whole (jumbo) 
4 whites (jumbo) 
3 slices 
3 tsp. 
2 cups 
180  
75 
300 
? 
200 
11:00 a.m. Rice (instant/white) 
baked chicken 
(boneless/white 
meat) 
olive oil 
hamburger on bun ( 
with ketchup, 
mustard, mayo, 
lettuce, tomato and 
onions) 
1 cup (dry) 
8 oz. 
 
2 tbs. 
4oz  
300 
300 
 
240 
360  
Time Food source Quantity (oz./cups) Calories (if known) 
    
    
    
    
    
    
    
    
    
    
Name:                                          Day:                           Date:   
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APPENDIX F 
 
UNCG CONSENT TO ACT AS A HUMAN PARTICIPANT 
 
 
Project Title: Acute effects of exercise on apelin, glucose, insulin and insulin sensitivity 
in apparently healthy individuals 
 
Principal Investigator and Faculty Advisor (if applicable): Justin Waller (PI) and Dr. 
Allan Goldfarb 
 
Participant's Name: ________ 
 
What is the study about? 
 
This is a research project. Your participation is voluntary. Your fat cells send signals to 
other tissues and one of these is known as apelin. The amount of fat you have influences 
blood apelin level and alters glucose balance and insulin sensitivity. Exercise serves as an 
excellent model to alter blood glucose levels and enhance insulin sensitivity. Apelin’s 
role on insulin sensitivity and glucose balance in response to acute exercise has not been 
investigated. We intend to determine how moderate and high intensity acute aerobic 
exercise influence blood apelin level, along with blood insulin and blood glucose. It is the 
purpose of this study to see if apelin levels in the blood change to either a high intensity 
aerobic exercise known to enhance blood glucose levels compared to a moderate intensity 
exercise known to maintain blood glucose levels. 
 
Why are you asking me? 
 
You are being asked to participate in this study because little research has been done 
regarding apelin and its effects on glucose homeostasis and insulin sensitivity in 
apparently healthy human subjects. You also fit our criteria of being between the ages of 
18-35. Prior to your participation, you will complete an American Heart 
Association/American College of Sports Medicine health fitness facility pre-participation 
screening questionnaire and a physical activity form. This is done in order to screen out 
individuals who may have musculoskeletal, cardiovascular or metabolic disorders that 
may interfere with the testing procedures or the measurements obtained, or women who 
may be pregnant or breast feeding. Only volunteers that do not use tobacco products 
(minimum 6 months) may be enrolled. Also, if you have been on any antioxidant 
supplement you must discontinue use for at least two weeks prior to being accepted as a 
subject. If you are taking any medication or drugs that may influence glucose, insulin or 
your metabolism/inflammation you will not be allowed to participate in this study. If your 
resting fasting blood glucose is above 100 mg/dl you will be excluded. If your resting 
blood pressure is elevated (140/90 mmHg) you will also be excluded from participating. 
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What will you ask me to do if I agree to be in the study? 
 
You will be asked to participate in this study through six (6) visits to our laboratory. Two 
of these visits will involve exercise and blood sampling. Another visit will involve 
ingestion of a glucose gel and blood sampling and three visits will only involve blood 
sampling. 
 
VISIT 1: You will be pre-screened for the information provided in the preceding section 
of this consent form. Screening will occur on the morning of your first visit. You will 
also bring a 3-day food record on your first visit listing amounts of food and drink. The 
time for this screening should be no longer than 15 minutes. 
 
After screening you will have your height, weight, blood pressure and body fat 
percentage (using a skinfold caliper at seven sites) determined. A resting blood sample 
from an arm vein will then be obtained (approximately 3 teaspoons, or 14 mls); you may 
feel slight discomfort or pain with the needle stick. You will then perform a graded 
treadmill run to determine your aerobic capacity (VO2max). The grade and speed of the 
treadmill will be increased gradually over time as you breathe through a mouthpiece 
connected to a tube to enable expired air samples to be measured for oxygen content. The 
test will continue until your aerobic capacity is reached or you indicate you can no longer 
maintain the pace or want to stop; you may feel some discomfort/fatigue during this test. 
There are bars on either side of the treadmill to grasp if needed. You will then be given a 
one-minute cool down/walk, after which another blood sample (3 teaspoons) will be 
obtained. Another resting, fasted blood sample (3 teaspoons) will be obtained 60 minutes 
after exercise. You will be provided water throughout this visit. You will press on the 
needle stick area for 2-5 minutes to avoid bruising after each of these blood samples is 
taken. The total time for this part of the visit will be no more than 1 hour and 45 
minutes. 
 
VISIT 2: After 24 hours you will visit the laboratory to have a 24-hr post-exercise blood 
sample (3 teaspoons) obtained; you must come in after an overnight (8-10 hrs) fast. The 
procedures for this blood draw will follow the same as the previous blood draws. The 
resting, fasted 24-hour blood sample will take less than 15 minutes to collect. 
 
VISIT 3: You will return to the lab at least 7 days after the initial graded run in the 
morning (same time and condition) to perform either a 30-minute run at a moderate 
intensity (75% of your aerobic capacity) or ingest a glucose gel about 50 grams). Your 
weight, blood pressure and resting heart rate will be determined as before. You will have 
blood taken at rest (3 teaspoons at each time point), immediately post-exercise (or gel 
consumption) and 60 minutes post-exercise (or gel consumption). Your heart rate and 
oxygen consumption will be monitored every 5 minutes during the run or after the 
ingestion of the gel. You will also give us feedback as to the difficulty of the exercise. 
You will be given water throughout this visit. You will also bring a 3-day food record 
prior to the third visit. The total time for this visit will be no more than 2 hours. 
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VISIT 4: After 24 hours you will visit the laboratory to have a 24-hr post-exercise blood 
sample (3 teaspoons) obtained; you must come in after an overnight (8-10 hrs) fast. The 
procedures for this blood draw will follow the same as the previous blood draws. The 
resting, fasted 24-hour blood sample will take less than 15 minutes to collect. 
 
VISIT 5: You will return to the lab at least 7 days after visit 3 in the morning (same time 
and condition) to perform the treatment you did not complete in visit 3. Your weight, 
blood pressure and resting heart rate will be determined as before. You will have blood 
taken at rest (3 teaspoons at each time point)), immediately post-exercise (or gel 
consumption) and 60 minutes post-exercise (or gel consumption). Your heart rate and 
oxygen consumption will be monitored every 5 minutes during the run or after the 
ingestion of the gel. You will also give us feedback as to the difficulty of the exercise. 
You will be given water throughout this visit. You will also bring a 3-day food record 
prior to the third visit. The total time for this visit will be no more than 2 hours. 
 
VISIT 6: After 24 hours you will visit the laboratory to have a 24-hr post-exercise blood 
sample (3 teaspoons) obtained; you must come in after an overnight (8-10 hrs) fast. The 
procedures for this blood draw will follow the same as the previous blood draws. The 
resting, fasted 24-hour blood sample will take less than 15 minutes to collect. 
 
This will conclude your study participation. Total participation time will be about 6.75 
hours. 
 
All information concerning your records will be kept confidential and you will not be 
identified in any presentation or published work. 
 
In addition, all blood samples obtained will be kept for possible future analyses and 
research, though you will not be identified in any way. 
 
You may contact the PI, Justin Waller, at jdwaller@uncg.edu or (336) 613-6899 or Dr. 
Allan Goldfarb at ahgoldfa@uncg.edu or (336) 334-3029 with any questions concerning 
the nature of your participation and your consent to participate in this research project. 
 
What are the risks to me? 
 
The specific risks associated with participation in this research project are listed below. 
 
You may feel tired and out of breath after the maximum aerobic capacity test which is 
normal. There is a very small risk of death as a result of this test (< 0.01%) and this is for 
all age groups and includes individuals that might have health problems. Since you are 
young and do not have any known health problems the risks associated with this test are 
reduced. You may let the researcher know if you are experiencing discomfort during the 
maximum aerobic capacity test, at which time the test will be discontinued. You may feel 
tired after the 30 minute run, which is normal. 
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It is possible that you may feel some symptoms of low blood sugar during either of the 
exercise sessions. Some of these symptoms are: 
 
 Shakiness or hand tremors  
 Ringing in the ears  
 Chills or clamminess  
 Lightheadedness or dizziness  
 Irritability  
 Nausea 
 
In the event that you feel these symptoms, you should immediately inform the researcher 
so that he/she may discontinue the test. To reduce the risk to you, a safety ‘spotter’ will 
be in place at all times during the testing period to assist you. 
 
Sterile techniques will be utilized to take the blood and there may be a small sensation of 
pain associated with taking blood. There may be some slight bruising associated with the 
blood sampling; placing direct pressure over the area where the blood was taken will 
minimize this. You must realize that infection can occur with any type of blood drawing 
but following sterile techniques will reduce this risk. 
 
If you have questions, want more information or have suggestions, please contact: Justin 
Waller at jdwaller@uncg.edu or (336) 613-6899 or Dr. Allan Goldfarb at (336) 334-3029 
or ahgoldfa@uncg.edu. 
 
If you have any concerns about your rights, how you are being treated, concerns or 
complaints about this project or benefits or risks associated with being in this study, 
please contact the Office of Research Integrity at UNCG toll-free at (855)-251-2351. 
 
What happens if I am injured during this study? 
 
UNCG is not able to offer financial compensation nor to absorb the costs of medical 
treatment should you be inured as a result of participating in this research study. 
However, we will provide a referral to your primary care physician. 
 
Are there any benefits to society as a result of me taking part in this research? 
 
This research project may advance the exercise science literature. Apelin has recently 
been reported to influence insulin sensitivity and glucose regulation, which carries 
important implications for the treatment of diabetes. Findings from this research project 
may advance future research in this area. 
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Are there any benefits to me for taking part in this research study? 
 
Through your participation in this study, you will learn of your maximal aerobic capacity, 
percent body fat and blood pressure. Additionally, you will be able to receive information 
on how you responded to the exercise sessions. You can ask for the blood glucose data to 
see if you maintained blood glucose balance on the 30 minute run. This information may 
be important in improving your overall health, and may serve as baseline data related to 
these measures. Otherwise, the information gathered in this study may not directly benefit 
you; however, it may advance the exercise science literature. 
 
Will I get paid for being in the study? Will it cost me anything? 
 
There are no costs to you or payments made to you for participating in this study. 
 
How will you keep my information confidential? 
 
All information concerning your records and obtained data will be kept confidential and 
you will not be identified in any presentation or published work. You will receive a study 
number, which will not be linked to your name. All records and data related to you, 
specifically, will be de-identified and coded and will be safely kept in a locked file 
cabinet. The master list for this study will also be codified with no identifying 
information. All study data will be destroyed, via document shredding and file erasure, 
upon publishing of the research data. This consent form will be kept for three years as 
required by federal law, after which time they will be destroyed to protect your identity. 
Blood samples will be properly disposed of after manuscripts have been published in 
accordance with biological hazard codes. All information obtained in this study is strictly 
confidential unless disclosure is required by law. 
 
What if I want to leave the study? 
 
You have the right to refuse to participate or to withdraw at any time, without penalty. If 
you do withdraw, it will not affect you in any way. If you choose to withdraw, you may 
request that any of your data which has been collected be destroyed unless it is in a de-
identifiable state. 
 
 
What about new information/changes in the study? 
 
If significant new information relating to the study becomes available which may relate 
to your willingness to continue to participate, this information will be provided to you. 
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Voluntary Consent by Participant: 
 
By signing this consent form/completing this survey/activity (used for an IRB-approved 
waiver of signature) you are agreeing that you read, or it has been read to you, and you 
fully understand the contents of this document and are openly willing consent to take part 
in this study. All of your questions concerning this study have been answered. By signing 
this form, you are agreeing that you are 18 years of age or older and are agreeing to 
participate, or have the individual specified above as a participant participate, in this 
study described to you by either Justin Waller or Dr. Allan Goldfarb. 
 
Signature: ________________________ Date: ________________ 
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APPENDIX G 
 
ACSM SKINFOLD MEASUREMENT PROCEDURES 
 
 
ACMS Resource Manual for Exercise Testing and Prescription (p.270) 
 
 
 
 
 
 
 
 
 
  
Copyright © 2010 American College of Sports Medicine
Figure 17-1. Skinfold Measures
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Skinfold 
Site 
Procedure  
Abdominal Vertical Fold 2 cm to the right side of the umbilicus 
Triceps Vertical Fold On the posterior midline of the upper arm, halfway 
between the acromion and olecranon processes, 
with the arm held freely to the side of the body 
Chest Diagonal Fold 1/2 the distance between the anterior axillary line 
and the nipple (men); or 1/3 the distance between 
the anterior axillary line and the nipple (women) 
Midaxillary Vertical Fold On the midaxillary line at the level of the xiphoid 
process of the sternum 
Subscapular Diagonal Fold (45° 
angle) 
1 to 2 cm below the inferior angle of the scapula 
Suprailiac Diagonal Fold In line with the natural angle of the iliac crest 
taken in the anterior axillary line immediately 
superior to the iliac crest 
Thigh Vertical Fold On the anterior midline of the thigh midway 
between the proximal border of the patella and the 
inguinal crease (hip) 
ACSM Resource Manual for Guidelines for Exercise Testing and Prescription pg. 
270 
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APPENDIX H 
 
RAW DATA 
 
 
Subject Characteristics 
 
Subje
ct 
Ag
e 
Gend
er 
Weig
ht 
(kg) 
Heig
ht 
(cm) 
BMI 
(kg/m
2) 
Siri 
BF%
Brozek 
BF% 
SAD 
(cm) 
WC 
(cm
) 
Hip 
(cm
) 
WH
R 
1 27 Male 66.1 172 22.3 6.69 7.43 18.2
5 
78 81 0.96
3
2 22 Fema
le 
59.15 155.
5
24.5 23.4
2
22.89 19.1 72.
5 
91.
2
0.79
3 29 Fema
le 
76.3 165.
5
27.8 32.3
3
31.11 24.8 83 104
.8
0.79
2
4 23 Fema
le 
65.55 177 20.9 16.5 16.5 18.2
5 
69 85 0.81
2
5  Male 79.85 182 24.2 10.6
8
11.11 21 81.
5 
100
.5
0.81
1
6 20 Male 68.05 177 21.7 7.67 8.34 18 71 91.
5
0.77
6
7 21 Male 105.3 182 31.9 23.3
6
22.82 27.1 97.
5 
115 0.84
8
8 21 Male 67.85 171 23.2 11.8
4
12.19 19 76.
5 
95 0.80
5
9 21 Fema
le 
56.05 167 20.1 18.2
1
18.07 17.5 72.
5 
92 0.78
8
10 21 Male 55.65 168 19.7 4.25 5.18 16.5 67.
5 
85 0.79
4
11 26 Male 64.9 164 24.1 13.6
4
13.84 20 80.
25 
94.
5
0.84
9
12 21 Fema
le 
63.6 169.
5
22.1 15.7
3
15.78 18.4 70 100 0.7
13 22 Male 60.05 177 19.2 7.87 8.53 17.6 68.
5 
89 0.76
9
14 21 Fema
le 
53.1 165 19.5 18.6
8
18.5 15.4 63.
5 
92.
4
0.68
7
15 20 Male 72.75 177 23.2 6.08 5.22 19.7
5 
77 97.
5
0.78
9
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Body Composition Measurements 
 
Subject Age Gender Chest 
(mm) 
Tricep
(mm) 
Axilla 
(mm) 
Sub-
scapular 
(mm) 
Abdominal 
(mm) 
Supra
-ilium 
(mm) 
Thigh 
(mm) 
Body 
Density
1 27 Male 3.85 4.2 5.85 8.85 11.2 10.15 5.75 1.08
2 22 Female 17.3
5
20.05 13.3 16.35 18.2 18.15 17.5 1.05
3 29 Female 29.0
5
27.65 27.95 16.25 30.4 21 30 1.03
4 23 Female 7.25 7.75 15.5 6 15.25 7 18.5 1.06
5  Male 9.1 7.3 9.15 13.2 19.3 9.2 9.9 1.07
6 20 Male 6.35 9.65 5.9 9 9.75 7.5 13.35 1.08
7 21 Male 21.7
5
27.65 24.1 24.3 33.15 25.2 23.05 1.05
8 21 Male 12.5 13.6 9.4 13.95 13.7 8.15 17.1 1.07
9 21 Female 8.25 14.5 8.75 8.5 15.5 9.75 23 1.06
10 21 Male 4.9 5 4.9 6 6.1 3.95 8.5 1.09
11 26 Male 9.05 9.9 12.35 15.3 20.2 9.9 19.8 1.07
12 21 Female 5.55 11.2 7.5 7.95 10.5 7.95 23.1 1.06
13 22 Male 5 5.6 6.1 10.65 14.3 6.35 13.25 1.08
14 21 Female 12.3
5
12.4 11.95 10.2 16 8.45 19.8 1.06
15 20 Male 5.2 6.3 5.2 8 6.9 5.1 9.35 1.09
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Reported Total kCal Consumed 
 
Subject  Total kcal 
1 
Total kcal 
2 
Total kcal 
3 
Avg total 
kCal 
1 male 1323 1270.5 1393.75 1329.08
2 female 1631.43 676.33 1583.25 1297
3 female 2827.33 2349.33 2247 2474.56
4 female 1617.67 2435.67 2287.5 2113.61
6 male 2271.67 2769.75 3045 2695.47
7 male 3471.75 3023 2769.5 3088.08
8 male 3000.75 3217 3636.25 3284.67
11 male 1038.75 903.5 1097.25 1013.17
12 female 1584.75 1436.33 1863.25 1628.11
13 male 1612 2235.25 2544.25 2130.5
14 female 1446.75 1450.25 1009 1302
15 male 3456.5 3969.33 3321 3582.28
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Reported CHO intakes 
 
Subject  CHO 1 (g) CHO2 (g) CHO 3 (g) Avg CHO (g) 
1 male 178.23 210.86 185.55 191.55
2 female 212.18 100.07 166.83 159.69
3 female 331.34 289.16 256.78 292.43
4 female 86.03 358.16 219.88 221.35
6 male 252.59 296.82 382.69 310.69
7 male 381.95 414.41 372.88 389.75
8 male 366.27 405.21 512.68 428.05
11 male 76.22 99.69 97.28 91.06
12 female 216.38 193 233.75 214.38
13 male 228.34 285.34 334.69 282.79
14 female 129.56 139.08 153.57 140.74
15 male 438.46 454.33 378.23 423.67
Subject  CHO 1 
(kCal)
CHO 2 
(kCal)
CHO 3 
(kCal)
Avg CHO 
(kCal)
1 male 712.93 843.45 742.2 766.19
2 female 848.7 400.27 667.32 638.76
3 female 1325.36 1156.64 1027.11 1169.70
4 female 344.12 1432.63 879.5 885.42
6 male 1010.35 1187.27 1530.77 1242.79
7 male 1527.79 1657.65 1491.51 1558.98
8 male 1465.06 1620.85 2050.7 1712.20
11 male 304.88 398.74 389.12 364.25
12 female 865.5 772.01 935.01 857.51
13 male 913.37 1141.34 1338.77 1131.16
14 female 518.22 556.33 614.28 562.94
15 male 1753.84 1817.33 1512.9 1694.69
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Reported Protein Intakes 
 
Subject  Protein 1 
(g) 
Protein 2 
(g) 
Protein 3 
(g) 
Avg Pro 
(g) 
1 male 80.91 61.90 69.15 70.65
2 female 81.20 21.72 64.55 55.82
3 female 114.36 96.48 98.54 103.12
4 female 122.62 81.79 128.35 110.92
6 male 157.86 184.45 195.91 179.41
7 male 98.97 72.22 88.71 86.63
8 male 143.37 153.14 159.89 152.13
11 male 77.65 56.45 77.75 70.62
12 female 76.25 50.56 69.35 65.39
13 male 58.38 77.46 90.89 75.58
14 female 80.78 91.01 43.90 71.89
15 male 142.8 157.38 146.57 148.81
 
Subject  Pro 1 
(kCal) 
Pro2 
(kCal) 
Pro 3 
(kCal) 
Avg Pro 
(kCal) 
1 male 323.65 247.58 276.59 282.61
2 female 324.79 86.87 258.21 223.29
3 female 457.43 385.91 394.15 412.49
4 female 490.48 327.16 513.4 443.68
6 male 631.43 737.79 783.65 717.62
7 male 395.86 288.88 354.82 346.52
8 male 573.48 612.54 639.54 608.52
11 male 310.59 225.81 310.98 282.46
12 female 305.02 202.23 277.38 261.54
13 male 233.51 309.85 363.54 302.3
14 female 323.13 364.02 175.58 287.58
15 male 569.9 629.53 586.27 595.23
 
107	
Reported Fat Intakes 
 
Subject  Fat 1 (g) Fat 2 (g) Fat 3 (g) Avg Fat 
(g) 
1 male 36.70 32.86 45.88 38.48
2 female 56.05 21.52 75.56 51.04
3 female 101.24 95.11 115.84 104.06
4 female 97.12 112.59 104.73 104.82
6 male 75.00 87.92 85.72 82.88
7 male 157.29 123.58 107.915 129.60
8 male 98.69 102.25 115.65 105.53
11 male 47.023 31.64 40.56 39.74
12 female 43.67 57.21 61.02 53.96
13 male 53.70 60.90 83.79 66.13
14 female 52.33 43.35 25.92 40.53
15 male 156.85 181.54 149.55 162.63
 
Subject  Fat 1 
(kCal) 
Fat 2 
(kCal) 
Fat 3 
(kCal) 
Avg Fat 
(kCal) 
1 male 330.26 295.76 412.92 346.31
2 female 504.47 193.65 680.06 459.40
3 female 911.16 856.02 1042.56 936.58
4 female 874.11 1013.34 942.57 943.34
6 male 675.03 791.30 771.45 745.93
7 male 1415.66 1112.22 971.24 1166.37
8 male 888.26 920.21 1040.85 949.77
11 male 423.20 284.74 365.04 357.66
12 female 392.99 514.86 549.14 485.66
13 male 483.32 548.12 754.09 595.18
14 female 470.97 390.17 233.26 364.8
15 male 1411.67 1633.83 1345.63 1463.71
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Reported SFA Intakes 
 
Subject  SFA 1 SFA 2 SFA 3 Avg SFA 
(g) 
1 male 12.26 9.48 15.88 12.54
2 female 17.59 5.96 18.77 14.11
3 female 18.54 24.06 28.10 23.57
4 female 22.85 34.31 28.58 28.58
6 male 29.10 27.88 29.58 28.85
7 male 45.91 40.82 37.86 41.53
8 male 24.40 26.21 27.99 26.20
11 male 18.61 12.59 14.28 15.16
12 female 13.27 16.03 20.01 16.44
13 male 22.31 29.09 32.71 28.04
14 female 23.39 14.03 8.15 15.19
15 male 45.48 60.92 51.93 52.78
 
Reported MUFA Intakes 
 
Subject  MUFA 1 MUFA 2 MUFA 3 Avg 
MUFA (g) 
1 male 47.04 50.55 44.16 47.25
2 female 17.72 7.73 30.35 18.60
3 female 26.27 30.62 52.29 36.39
4 female 27.38 31.07 31.87 30.11
6 male 16.07 37.04 26.82 26.64
7 male 40.42 48.51 35.78 41.57
8 male 38.43 32.06 44.84 38.45
11 male 16.89 11.11 15.69 14.56
12 female 14.54 16.08 19.20 16.61
13 male 15.53 12.82 24.44 17.60
14 female 5.09 14.65 8.39 9.377
15 male 51.07 54.39 48.57 51.34
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Reported PUFA Intakes 
 
Subject  PUFA 1 PUFA 2 PUFA 3 Avg PUFA (g) 
1 male 7.98 7.31 7.15 7.48 
2 female 15.63 6.70 18.43 13.58 
3 female 18.93 14.37 32.68 21.99 
4 female 88.39 34.05 42.46 54.96 
6 male 10.51 21.29 16.05 15.95 
7 male 45.56 23.32 19.22 29.36 
8 male 25.12 22.99 32.75 26.95 
11 male 4.45 5.15 7.91 5.84 
12 female 11.39 16.69 12.28 13.46 
13 male 10.81 9.74 18.59 13.05 
14 female 3.53 6.34 5.06 4.98 
15 male 27.39 23.74 31.06 27.39 
 
Reported Vitamin A Intakes 
 
Subject  Vit A1 
(mg) 
Vit A2 
(mg) 
Vit A3 
(mg) 
AvgVit A 
(mg) 
Vit A% of RDA 
1 male 1.43 2.66 2.05 2.05 1.40 
2 female 0.40 0.13 0.25 0.26 0.23 
3 female 0.27 0.36 0.81 0.48 0.44 
4 female 0.80 0.30 1.71 0.94 0.72 
6 male 1.36 1.38 3.07 1.94 0.41 
7 male 1.15 1.37 1.01 1.18 0.47 
8 male 1.93 1.94 1.76 1.88 0.50 
11 male 1.04 0.63 0.41 0.69 0.46 
12 female 3.30 3.96 1.74 3.00 0.63 
13 male 0.61 0.43 2.87 1.30 0.48 
14 female 0.36 0.44 0.40 0.399 0.61 
15 male 2.93 1.95 2.68 2.52 0.541 
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Reported Vitamin C Intakes 
 
Subject  Vit C1 
(mg) 
Vit C2 
(mg) 
Vit C3 
(mg) 
AvgVit C 
(mg) 
Vit C % 
RDA 
1 male 256.1 463.73 490.05 403.29 5.45 
2 female 110.40 14.2 59.55 61.38 0.79 
3 female 54.35 132.9 6.09 64.45 0.081 
4 female 16.5 58.16 135.45 70.04 1.81 
6 male 189.38 66.61 50.36 102.11 0.56 
7 male 70.01 80.9 85.98 78.96 0.96 
8 male 145.33 77.43 220.47 147.74 2.45 
11 male 45.63 80.6 84.05 70.09 0.93 
12 female 314.51 165.87 64.21 181.53 0.86 
13 male 19.75 76.73 58.78 51.75 0.65 
14 female 208.48 24.88 32.31 88.55 0.431 
15 male 168.98 113.1 153.12 145.08 1.70 
 
Reported Vitamin E Intakes 
 
Subject  Vit E1 
(mg) 
Vit E2 
(mg) 
Vit E3 
(mg) 
AvgVit E 
(mg) 
Vit E % RDA 
1 male 9.99 12.31 10.62 10.97 0.707 
2 female 12.02 12.90 20.64 15.18 1.376 
3 female 4.97 8.61 14.33 9.30 0.955 
4 female 8.13 16.10 68.14 30.79 4.542 
6 male 6.31 26.27 42.10 24.89 2.806 
7 male 18.22 48.94 22.83 30.00 1.522 
8 male 58.75 45.99 35.20 46.64 2.35 
11 male 3.89 5.14 3.12 4.05 0.208 
12 female 10.96 11.97 10.69 11.21 0.713 
13 male 4.42 5.39 6.49 5.43 0.432 
14 female 4.81 5.27 3.33 4.47 0.222 
15 male 12.75 13.51 13.63 13.30 0.9084 
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Reported Zinc Intakes 
 
Subject  Zinc 1 
(mg) 
Zinc 2 
(mg) 
Zinc 3 
(mg) 
Avg Zinc 
(mg) 
Zinc % RDA 
1 male 12.27 7.92 12.34 10.84 1.12 
2 female 12.08 3.53 7.47 7.69 0.93 
3 female 7.59 9.33 8.83 8.58 1.10 
4 female 10.81 10.39 9.29 10.16 1.16 
6 male 13.11 19.81 21.21 18.04 1.93 
7 male 9.19 9.37 8.34 8.97 0.76 
8 male 20.35 26.02 28.49 24.95 2.59 
11 male 14.52 6.10 8.75 9.79 0.79 
12 female 8.58 6.43 7.64 7.55 0.96 
13 male 6.17 6.12 9.49 7.26 0.86 
14 female 2.42 11.47 6.62 6.83 0.83 
15 male 20.61 35.18 20.83 25.54 1.89 
 
Plasma Apelin Concentrations at Rest 
 
Subject  Apelin A Apelin B Apelin C Average 
Apelin 
1 male 0.393 0.270 0.424 0.3623
2 female 0.627 0.578 0.503 0.5693
3 female 0.784 0.575 0.832 0.7303
4 female 0.564 1.186 0.641 0.797
6 male 0.268 0.2235 0.290 0.2605
7 male 0.649 1.228 1.377 1.0847
8 male 0.907 0.714 0.945 0.8553
11 male 0.505 0.2435 0.218 0.3222
12 female 0.701 0.332 0.193 0.4087
13 male 0.112 0.364 0.246 0.2407
14 female 0.582 0.304 0.237 0.3743
15 male 0.112 0.109 0.1535 0.1248
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Macronutrient Intake – Percentage of total kCal 
 
 Total Male Female 
CHO  48.52% 49.47% 46.67%
Protein 18.37% 18.31% 18.47%
Fat 33.98% 32.85% 36.18%
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APPENDIX I 
 
APELIN VAIRABILITY 
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